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A non-linear approach, consistent with available mode of action (MOA) data, is most scientiﬁcally
defensible for assessing the carcinogenicity of oral exposure to hexavalent chromium (CrVI). Accordingly,
the current paper builds upon previous studies (Haney, 2015a, 2015b) to ﬁrst develop a non-linear, non-
threshold approach as well as a non-linear threshold approach for assessing the oral carcinogenicity of
CrVI, and then utilizes available MOA analyses and information for selection of the most scientiﬁcally-
supported approach. More speciﬁcally, a non-linear, non-threshold doseeresponse function was devel-
oped that adequately describes the non-linearity predicted for potential human excess risk versus oral
dose due to the sub-linear relationship between oral dose and internal dose (added mg Cr/kg target
tissue) across environmentally-relevant doses of regulatory interest. Additionally, benchmark dose
modeling was used to derive a reference dose (RfD of 0.003 mg/kg-day) with cytotoxicity-induced
regenerative hyperplasia as a key precursor event to carcinogenesis in the mouse small intestine. This
RfD value shows remarkable agreement with that published previously (0.006 mg/kg-day) based on a
more scientiﬁcally-sophisticated, physiologically-based pharmacokinetic modeling approach (Thompson
et al., 2013b). The RfD approach is the most scientiﬁcally-defensible approach based on the weight-of-
evidence of available MOA information and analyses conducted for the most scientiﬁcally-supported
MOA.
© 2015 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
A signiﬁcant amount of new research has been conducted over
the past several years to generate data speciﬁcally to better inform
the mode of action (MOA) analysis for hexavalent chromium-
induced carcinogenesis due to oral exposure and to improve the
extrapolation of rodent oral study results to humans (e.g.,
Thompson et al., 2011a, 2011b, 2012a, 2013a; Kirman et al., 2012,
2013; Proctor et al., 2012; Kopec et al., 2012a, 2012b; O'Brien
et al., 2013; Suh et al., 2014; Thompson et al., 2015a, 2015c).
Thorough evaluation of these research project data is essential to a
better scientiﬁc understanding of the carcinogenic MOA operating
in relevant rodent studies (e.g., NTP, 2008) and hexavalent chro-
mium (CrVI) toxicokinetics following oral exposure, both of which
are of particular importance considering the signiﬁcant regulatory
challenge of extrapolating high oral dose results from laboratoryInc. This is an open access article uanimal studies to environmentally-relevant human doses that are
orders of magnitude lower in a meaningful (not just conservative),
toxicologically-predictive manner (e.g., the mouse dose at the
lowest water concentration used in NTP, 2008 is about 74,000 times
higher than the approximate human dose corresponding to the 35-
city geometric mean drinking water concentration reported in
EWG, 2010). Consequently, regulatory agencies should duly
consider these data to inform key areas of chemical doseeresponse
assessment such as the MOA (e.g., key events), toxicokinetics (e.g.,
dose-dependent differences in target tissue absorption), and
biologically-plausible expectations about potential thresholds and
any low-dose risk.
Failure of a chemical assessment's low-dose extrapolation to
appropriately consider and incorporate (if scientiﬁcally robust and
defensible) relevant CrVI research project data on MOA and tox-
icokinetics may result in signiﬁcantly overestimating environ-
mental risk. For example, recent analyses of CrVI toxicokinetic data
(Kirman et al., 2012) revealed appreciable dose-dependent differ-
ences in target tissue absorption (Haney, 2015a, 2015b). Morender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tissues per unit dose) progressively decreases with decreasing oral
dose, resulting in non-linearity (i.e., sub-linearity) between oral
dose and target tissue dose across doses of environmental interest
(Fig. 1, reproduced from Fig. 2 in Haney, 2015b). This type of tox-
icokinetic information that reveals a non-linear relationship be-
tween oral and internal dose should be taken into account in
assessing the potential for a non-linear doseeresponse (USEPA,
2005). Taking this non-linear/sub-linear relationship between
oral and internal target tissue CrVI dose into account, Haney
(2015b) concluded:
 Decreasing target tissue absorption as doses decrease to lower,
more environmentally-relevant doses is inconsistent with linear
low-dose extrapolation as the shape of the doseeresponse curve
accounting for this toxicokinetic phenomenon would be non-
linear;
 The magnitude of risk overestimation by a linear low-dose
extrapolation approach (e.g., the USEPA draft oral slope factor
or SFo) increases signiﬁcantly as it is used to predict risk at
lower, more environmentally-relevant CrVI doses where the
dose fractions absorbed by target tissues progressively decrease;
and
 A non-linear approach, consistent with available MOA data, is
most scientiﬁcally defensible for assessing CrVI-induced
carcinogenesis.
Accordingly, consistent with results from prior toxicokinetic
analyses demonstrating a non-linear/sub-linear relationship be-
tween oral dose and internal dose (i.e., target tissue concentration),
the current paper builds upon previous studies (Haney, 2015a,
2015b) to:
1) Develop two non-linear approaches (i.e., non-linear, non-
threshold and threshold) for assessing the carcinogenicity of
oral exposure to CrVI; and
2) Utilize available published MOA analyses and information for
selection of the most scientiﬁcally-supported approach.
The non-linear, non-threshold approach considered is a novel
one for assessing the potential risk of oral exposure to CrVI. The
non-linear, threshold approach is represented by the derivation of a
reference dose (RfD). While other RfD values have been developed,
the RfD derived herein is based on an internal dose metric (unlike
the draft RfD in USEPA, 2010), focuses speciﬁcally on the duodenum
as the most tumorigenically responsive target tissue (unlikeFig. 1. Dose-dependent changes in mouse target tissue absorption per unit dosThompson et al., 2013b), and converts internal dose to external
dose based on an independently modeled relationship (Haney,
2015a), thus providing an important point of comparison for pre-
viously derived values. Lastly, while the MOA data reviewed herein
have been discussed in various studies elsewhere (e.g., Thompson
et al., 2013a), this study represents the ﬁrst review and interpre-
tation of all these data (including newly published studies) to
appear in a peer-reviewed scientiﬁc journal by staff of a regulatory
agency. The regulatory perspective is important because regulatory
agencies ultimately determine what low-dose extrapolation ap-
proaches are scientiﬁcally justiﬁed and any impact of new MOA
research on health-protective regulations.
2. Materials and methods
Pursuant to prior analyses and justiﬁcation provided in Haney
(2015b), this paper considers two non-linear approaches for
assessing the carcinogenicity of oral exposure to CrVI:
 A non-linear, non-threshold low-dose extrapolation approach;
and
 A non-linear threshold approach.
The non-linear, non-threshold low-dose extrapolation approach
is exempliﬁed by the development of a mathematical model (i.e.,
doseeresponse function) that adequately describes the non-
linearity that would be predicted in excess risk versus oral dose,
under the preliminary assumption that excess risk is proportional
to target tissue concentration of absorbed CrVI down to zero dose
(i.e., under an assumed mutagenic MOA for the sake of compari-
son), when dose-dependent differences in target tissue absorption
are appropriately considered. These differences are discussed in
Haney (2015a), which provides a peer-reviewed approach to
calculate dose-speciﬁc adjustment factors for the draft SFo (USEPA,
2010) based on dose-dependent differences in absorption. These
dose-speciﬁc adjustment factors that account for the non-linearity
in oral dose versus target tissue concentration were used in a sec-
ond study (Haney, 2015b) to estimate potential excess risk at
environmentally-relevant doses (e.g., doses at the federal
maximum contaminant level (MCL), 1/3 the MCL, measured
drinking water concentrations) and produce an associated dos-
eeresponse curve (Fig. 2, reproduced from Fig. 3 of Haney, 2015b).
The doseeresponse is non-linear due to the non-linear (i.e., sub-
linear) toxicokinetics of CrVI absorption by target tissues being
taken into account (Fig. 1) (also see Fig. 4 of Haney, 2015a). It is this
non-linear/sub-linear doseeresponse for excess risk whichmust bee and low-dose nonlinearity in absorbed tissue concentration versus dose.
Fig. 2. Potential human excess risk versus lower dose adjusted for dose-dependent differences in target tissue absorption.
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exemplify the non-linear, non-threshold low-dose extrapolation
method.
Although themethods provided in Haney (2015a) can be used to
more accurately estimate potential carcinogenic risk at a given oral
dose while accounting for dose-dependent changes in target tissue
absorption, relatively burdensome dose-speciﬁc calculations are
required. Therefore, a more practical and user-friendly approach is
desirable for calculating excess risk which is non-linear with dose.
Such an approach is achieved in this paper through a model (i.e.,
doseeresponse function) that makes the calculation of potential
excess risks at various doses (accounting for dose-dependent
changes in target tissue absorption) much simpler. More specif-
ically, the doseeresponse function describing the predicted non-
linear relationship between excess risk and oral dose was ob-
tained by modeling the human doses and excess risk estimates
from Table 3 of Haney (2015b), reproduced for the current study as
Table 1, using USEPA benchmark dose (BMD) software (BMDS
version 2.5). An additional dose evaluated in Haney (2015b), the
approximate adult human intake at the federal MCL (3E-03 mg/kg-
day), was also included in Table 1. Consistent with the deﬁnition of
excess risk, excess risk was set to zero at 0 mg/kg-day. The devel-
opment of this model serves as a suitable example of the non-
linear, non-threshold low-dose extrapolation method for the cur-
rent paper.
The non-linear threshold approach is represented in this paperTable 1
Human excess risk estimates adjusted for dose-dependent differences in absorption by t
Mouse dosea mg/kg-day (at water concentration) SFo adjustment factorb
4.3E-05 (35-city GM of 0.00018 mg/L) 2408
3.1E-03 (highest city of 0.0129 mg/L) 34
8.0E-03 (1/3 MCL of 0.0333 mg/L) 6.2
1.8E-02 4.8
2.4E-02 (MCL of 0.1 mg/L) 4.3
1.165Eþ00 (male mouse POD/BMDL10) 1
a Doses from the federal MCL down to 1/3 MCL from Table 9 of Haney (2015a) or text o
MCL; BMDL10 from USEPA (2010).
b From Table 9 or text of Haney (2015a, 2015b).
c Human dose ¼ mouse dose/(70 kg/0.05 kg)0.25 except for one dose (see last footnot
d Adjusted risk based on unrounded SFo of 0.525 per mg/kg-day (i.e., 0.1 risk/human
e Corresponds to approximate human intake at the federal MCL: (0.1 mg/L 2 L/day)/by the derivation of an RfD designed to be protective of the po-
tential carcinogenic effects of oral exposure to CrVI. While this
approach already appears in the peer-reviewed literature
(Thompson et al., 2013b), differences in the analyses result in
somewhat different RfD values. For example, the extensive
physiologically-based pharmacokinetic (PBPK) modeling used in
Thompson et al. (2013b) to derive the mouse internal dose metric
for BMD modeling (ﬂux of CrVI into target tissues) and ultimately
the human point-of-departure (POD) could not be conducted for
the current study. Consequently, an alternative analysis was per-
formed, which can be used for comparison to the Thompson et al.
(2013b) RfD (0.006 mg/kg-day).
The RfD for this paper was developed using standard dos-
eeresponse assessment methodologies (e.g., TCEQ, 2012; USEPA,
1993) and USEPA BMD software (BMDS version 2.5), with diffuse
hyperplasia as a key (i.e., necessary but not always sufﬁcient) pre-
cursor event in the proposed non-mutagenic MOA for CrVI-induced
carcinogenesis (Thompson et al., 2013a) since available data indi-
cate that it precedes tumor formation in the mouse small intestine
(e.g., Fig. 1 of Thompson et al., 2011a, Fig. 3 of Thompson et al.,
2013b). Based on NTP (2008) data, diffuse hyperplasia only has a
strong, well-deﬁned doseeresponse relationship in the mouse
duodenum (see Appendices C and D of NTP, 2008). This is consis-
tent with both signiﬁcant tissue absorption of CrVI by the duo-
denum (duodenum tissue concentration > jejunum > ileum;
Table 8 of Kirman et al., 2012) and the duodenum as the mostarget tissues.
Human equivalent dose for
modelingc mg/kg-day
Excess risk adjusted for dose-dependent
absorption for modelingd
7.1E-06 1.5E-09
5.1E-04 7.9E-06
1.3E-03 1.1E-04
3.0E-03e (at MCL of 0.1 mg/L) 3.1E-04
3.9E-03 4.7E-04
1.9E-01 1.0E-01
f Haney (2015b), lower doses based on ratio of water concentration to MCL dose at
e).
dose of 0.1905) x human equivalent dose/SFo adjustment factor.
70 kg z 0.003 mg/kg-day.
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selected as the critical mouse target tissue for BMD analysis. More
speciﬁcally, the incidence of diffuse hyperplasia in the duodenum
of female mice was used for BMD modeling since:
 Statistical analyses did not reveal differences between male and
female mice in hyperplastic or tumorigenic response to CrVI
exposure (Thompson et al., 2013b);
 The doseeresponse for diffuse hyperplasia in female mice is
strong and more monotonic than that in male mice (see
Tables C4 and D4 of NTP, 2008); and
 Importantly, the water concentrations used in NTP (2008) for
female mice correspond to those used in Kirman et al. (2012) to
determine added Cr concentrations in mouse target tissues due
to CrVI oral exposure, which is a very useful internal dose metric
for BMD modeling.
Accordingly, the incidence of diffuse hyperplasia in the duo-
denum of female mice from NTP (2008) along with the duodenum
tissue concentrations (added mg Cr/kg tissue) reported in Kirman
et al. (2012) were used for BMD modeling in the principal anal-
ysis. Additionally, the estimated 95% lower conﬁdence limits (95%
LCLs) on duodenum tissue concentrations were used for a sup-
porting analysis for comparison of BMD results from the principal
analysis with a more conservative, alternate BMD analysis. A
benchmark response (BMR) of 10% was used so that the BMD and
95% lower conﬁdence limit on the BMD (BMDL) would be calcu-
lated at a BMR that does not extrapolate farther than necessary
below the range of the data. That is, so that the study data (e.g., a
diffuse hyperplasia incidence of 32% (16/50) at the lowest dose) can
provide support to the BMD10/BMDL10 values.
Lastly, while the more detailed data analyses and lengthy dis-
cussions found in stand-alone MOA analysis papers are beyond the
scope of this paper, published MOA analyses and the underlying
data (McCarroll et al., 2010; Thompson et al., 2011b, 2013a) are
brieﬂy reviewed to assess the overall weight-of-evidence for the
most scientiﬁcally-supported MOA (i.e., mutagenic versus non-
mutagenic/threshold) for CrVI-induced carcinogenesis due to oral
exposure through summary and interpretation of the currently
available scientiﬁc evidence and its strength. See Section 3.3.3.1 for
additional details. This weight-of-evidence is used for selection of
the most scientiﬁcally-defensible, non-linear approach (i.e., non-
threshold versus threshold).3. Results
3.1. Non-linear, non-threshold low-dose extrapolation approach
3.1.1. BMD modeling
The Weibull model had the lowest Akaike Information Criterion
(AIC) and was the only model that provided ﬁt to the datasetTable 2
Weibull model response function ﬁt to modeled doseeresponse data.
Weibull model equation: Y ½excess risk ¼ background þ ð1  backgroundÞð1 2:7
Parameters Values for Model ﬁt with full set of doseeresponse
dataa
Values
(two h
Dose (mg/kg-day) for user input to estimate potential excess risk for use
excess
Background 0 4.7284
Slope 7.08154 67.343
Power 1.8147 2.1009
Solve for Y [excess risk]:
a See Table 1 for doseeresponse (i.e., human dose-excess risk) data; Weibull model w
b Corresponds to approximate human intake at the federal MCL.(Table 1) with a goodness-of-ﬁt p value > 0.1 and scaled residuals
<j2j (BMDS Wizard version 1.10, BMDS version 2.5). The equation
and parameter values for the Weibull model doseeresponse func-
tion (provided by BMD software) ﬁt to the full dataset are provided
in Table 2. However, while the model ﬁt to all doses in Table 1 (i.e.,
the full dataset) provided acceptable ﬁt per goodness-of-ﬁt criteria,
visual inspection revealed a less-than-desirable ﬁt at doses of in-
terest for environmental risk assessment (Fig. 3). Dropping the
highest dose substantially improved model ﬁt at all doses. Impor-
tantly, this includes doses corresponding to water
concentrations  the MCL, which are the doses of most interest for
environmental risk assessment. The absolute values of scaled re-
siduals for all doses decreased and the goodness-of-ﬁt p value
increased (Table 3), with substantially improved ﬁt compared to the
full dataset model conﬁrmed by visual inspection for doses of in-
terest (Fig. 3). Similarly, dropping the two highest doses also pro-
vided a better-ﬁtting model compared to modeling the full dataset
(see Fig. 3, parameter values provided in Table 2). However,
compared to dropping only the highest dose: (1) this results in the
loss of more information (an additional data point); (2) the scaled
residual for zero dose increases; (3) the scaled residual for the
lowest dose is not improved; (4) the scaled residuals for the two
middle non-zero doses are only marginally improved; and (5) the
scaled residual for the approximate human dose corresponding to
the MCL increases over 2-fold, with the average of the absolute
values of scaled residuals being slightly higher compared to only
dropping the highest dose (Table 3). Moreover, higher doses should
only be dropped for modeling one dose at a time until adequate
model ﬁt is obtained (USEPA, 2012), and only dropping the highest
dose was necessary to accomplish satisfactory model ﬁt by visual
inspection, a goodness-of-ﬁt p value > 0.1, and scaled residuals <j2j.
For the reasons discussed above, the Weibull model ﬁt dropping
only the highest dose is deemed the most appropriate, best-ﬁtting
model. While models considered to provide overall poorer ﬁts
(using the full dataset or dropping the two highest doses) are also
shown in Fig. 3 for comparison, these models are not considered
further.3.1.2. Non-linear, non-threshold doseeresponse model
Fig. 3 shows the best-ﬁttingmodel for the dosesmodeled, which
include those of most interest for environmental risk assessment
(i.e., doses corresponding to water concentrations  the MCL). The
model equation and parameter estimates for this best-ﬁttingmodel
(provided by BMD software) are provided in Table 2 and represent
the non-linear, non-threshold low-dose extrapolation approach for
this paper. Table 4 provides a comparison of the dose-speciﬁc
excess risks used for modeling (from Table 1) to the excess risks
predicted by the best-ﬁtting model (Weibull model with highest
dose in Table 1 dropped). Across doses, the average difference be-
tween the excess risks used for modeling and the excess risks
predicted is 12.7%. Furthermore, the potential excess risks2ðslopedose
powerÞÞ
for better-ﬁtting Model
ighest doses dropped)a
Values for best-ﬁtting model
(high dose dropped)a
Example
calculation
r input to estimate potential
risk
for user input to estimate
potential excess risk
0.003b
7E-10 6.95107E-11 6.95107E-11
8 38.3192 38.3192
6 2.02543 2.02543
3.0E-04
ith highest dose dropped is best-ﬁtting model.
Fig. 3. Non-linear, non-threshold model ﬁt for potential human excess risk versus lower dose adjusted for dose-dependent differences in target tissue absorption.
Table 3
Goodness-of-ﬁt P values and scaled residuals for Weibull model ﬁt to full set of data and subsets.
Human equivalent dosea
mg/kg-day
Scaled residuals for model ﬁt with
full set of doseeresponse datab
(p value ¼ 0.3405)
Scaled residuals for better-ﬁtting model
(two highest doses dropped)b
(p value ¼ 0.7822)
Scaled residuals for best-ﬁtting
model (high dose dropped)b
(p value ¼ 0.8958)
0 0.000 0.022 0.008
7.1E-06c 0.955 0.001 0.001
5.1E-04d 0.144 0.087 0.111
1.3E-03 1.078 0.679 0.748
3.0E-03e 0.900 0.148 0.073
3.9E-03 0.974 e 0.160
1.9E-01 1.345 e e
Overall averagef: 0.771 0.187 0.183
a From Table 1.
b P values and scaled residual values from USEPA BMD software (BMDS version 2.5) output.
c Human dose ¼ mouse dose at 35-city drinking water GM of 0.00018 mg/L (EWG, 2010)/(70 kg/0.05 kg)0.25.
d Human dose ¼ mouse dose at highest water concentration of 0.0129 mg/L (EWG, 2010)/(70 kg/0.05 kg)0.25.
e Corresponds to approximate human intake at the federal MCL.
f Averages obtained using the absolute values of the scaled residuals.
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drinking water concentrations (i.e., the 35-city GM of 0.00018 mg/L
and highest city drinking water concentration of 0.0129 mg/L in
EWG, 2010) are of particular interest to regulatory agencies and are
remarkably within ±3.8% of the excess risks used for modeling (seeTable 4
Comparison of excess human risks used for modeling versus excess risks predicted by th
Human equivalent dosea mg/kg-day Excess risk modeleda
7.1E-06c 1.5E-09
5.1E-04d 7.9E-06
1.3E-03 1.1E-04
3.0E-03e 3.1E-04
3.9E-03 4.7E-04
Overall average:
a From Table 1.
b Weibull model with highest dose from Table 1 dropped is best-ﬁtting model; equat
c Human dose ¼ mouse dose at 35-city drinking water GM of 0.00018 mg/L (EWG, 20
d Human dose ¼ mouse dose at highest water concentration of 0.0129 mg/L (EWG, 20
e Corresponds to approximate human intake at the federal MCL.italicized values in Table 4). These results are indicative of a rela-
tively practical and user-friendly non-linear, non-threshold model
that overall, adequately describes the non-linearity in potential
excess risk versus oral dose across the doses of most environmental
interest.e best-ﬁtting model.
Excess risk predicted by best-ﬁtting modelb Difference (%)
1.5E-09 0
8.2E-06 3.8
5.5E-05 50
3.0E-04 3.2
5.0E-04 6.4
12.7
ion provided in Table 2.
10)/(70 kg/0.05 kg)0.25.
10)/(70 kg/0.05 kg)0.25.
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3.2.1. BMD modeling
The Log-Logistic and Dichotomous-Hill models provided
adequate ﬁt to the mouse data (Table 5) with a goodness-of-ﬁt p
value > 0.1 and scaled residuals <j2j (BMDS Wizard version 1.10,
BMDS version 2.5), conﬁrmed by visual inspection. These models
provided almost identical ﬁts (Fig. 4) with the lowest AIC value,
highest goodness-of-ﬁt p value, the same BMD10 values and very
similar BMDL10 values (Table 6). The mouse BMD10 value was 1.83
added mg Cr/kg tissue for both models using mean added mg Cr/kg
tissue as the internal dose metric. Interestingly, this is the same
BMD10 value calculated in Thompson et al. (2013b) for their internal
dose metric (BMD10 of 1.8 based on intestinal ﬂux of mg Cr absor-
bed/kg tissue-day). Conservatively using the 95% LCL of duodenum
tissue concentrations as the internal dose metric for modeling
diffuse hyperplasia in the duodenum resulted in the very similar
BMD10 value of 1.74 added mg Cr/kg tissue for both models. The
BMDL10 values showed good agreement with their corresponding
BMD10 values, all being within a factor of 1.5. Interestingly, the
BMDL10 value for bothmodels usingmean addedmg Cr/kg tissue as
the internal dose metric (1.4 added mg Cr/kg tissue rounded to two
signiﬁcant ﬁgures) is the same as the BMDL10 value calculated in
Thompson et al. (2013b) for their internal dose metric (BMDL10 of
1.4 based on intestinal ﬂux of mg Cr absorbed/kg tissue-day).
Furthermore, the BMDL10 values using mean added mg Cr/kg tis-
sue as the internal dose metric were very similar to those using the
95% LCL of tissue concentrations (i.e., within a factor of 1.2). This
increases conﬁdence in the principal analysis and use of the
average BMDL10 value of 1.39 for mean added mg Cr/kg duodenum
tissue (Table 6) as the POD. Thus, a mouse BMDL10 of 1.39 addedmg
Cr/kg tissue will be used as the POD for diffuse hyperplasia in the
duodenum for the derivation of an RfD.3.2.2. Conversion of internal POD to external POD dose
As an internal dose metric, the mouse POD of 1.39 added mg Cr/
kg duodenum tissue must be converted to a corresponding oral
dose (i.e., units of mg/kg-day) for derivation of the RfD. The rela-
tionship between duodenum tissue concentration (mean mg Cr/kg
tissue) and oral dose (mg/kg-day) was modeled in a previous study
(Haney, 2015a) using tissue concentration data reported by Kirman
et al. (2012). The associated ﬁgure and table (Fig. 1 and Table 6 in
Haney, 2015a) are reproduced in the current study as Fig. 5 and
Table 7. Fig. 5 shows good ﬁt for the Hill model (goodness-of-ﬁt was
evaluated by visual inspection with scaled residuals <j2j and a
goodness-of-ﬁt p value > 0.1). The equation and parameter esti-
mates for this doseeresponse function (provided by BMD software)
were used to calculate the oral dose corresponding to the POD
duodenum tissue concentration of 1.39 added mg Cr/kg tissue.
Importantly, the POD tissue concentration falls between two of theTable 5
Added chromium duodenum concentrations in B6C3F1 mice.
Drinking water
concentrationa (mg SDD/L)
Duodenum tissue concentrationa
(mean added mg Cr/kg tissue)
±SDa 95% UCLb
(added mg
0 0 e e
14 7.2 0.8 7.8
60 33.5 5.0 37.2
170 42.4 12.4 51.5
520 60.9 14.1 71.3
a From Table 8 of Kirman et al. (2012) with zero shown for added Cr at zero dose.
b 95%UCL ¼ mean þ (1.645  SE) where SE ¼ SD/n0.5 and n ¼ 5.
c 95%LCL ¼ mean  (1.645  SE) where SE ¼ SD/n0.5 and n ¼ 5.
d From Table D4 of NTP (2008).duodenum tissue concentrations modeled and is similar to one of
themodeled concentrations (1.5mg/kg tissue) where the estimated
and observed values show excellent agreement (i.e., the scaled
residual is 0.421, well below j2j), which increases conﬁdence in the
estimate at the POD. As shown in Table 7, a mouse oral dose of
0.31 mg/kg-day is estimated to correspond to the POD duodenum
tissue concentration. Note that the application of an animal-to-
human uncertainty factor to this mouse POD ultimately results in
a value (0.031 mg/kg-day) that is below the lower end of the range
of average human equivalent doses (HED values of 0.05e0.1 mg/kg-
day) cited in a recent USEPA CrVI PBPK study (Sasso and Schlosser,
2015), practically identical to the more conservative HED of
0.028 mg/kg-day (pH ¼ 5) based on a similar evaluation (e.g., using
the BMDL10 for diffuse epithelial hyperplasia), and is 4.5-fold lower
than the HED of 0.14 mg/kg-day (pH ¼ 2.5) based on the similar
evaluation (see Table 1 of Sasso and Schlosser, 2015). This mouse
oral dose POD (0.31 mg/kg-day) will be used to derive an RfD
designed to be protective of both non-carcinogenic and carcino-
genic effects (i.e., using diffuse hyperplasia as a key precursor event
to tumor formation in the small intestine, protecting against hy-
perplasia should preclude tumorigenesis).3.2.3. RfD derivation
An RfD is calculated by dividing the POD by applicable uncer-
tainty factors to reﬂect data limitations and to derive a value that is
below levels where health effects would be expected to occur
(TCEQ, 2012). The three applicable uncertainty factors (UFs) are the:
 Animal-to-human uncertainty factor (UFA);
 Intrahuman uncertainty factor (UFH); and the
 Database uncertainty factor (UFD).
The values selected for these UFs are the same as those selected
in USEPA (2010). A full UFA of 10 was used to account for inter-
species differences in CrVI toxicokinetics and toxicodynamics.
Additionally, a full UFH of 10 was used to account for intrahuman
variability in toxicokinetics and toxicodynamics as such differences
could lead to variability in susceptibility (e.g., proton pump inhib-
itor (PPI) use increases lifetime average daily dose by 7e10%
depending on the internal dose ﬂux metric used; Thompson et al.,
2013b). Lastly, an UFD of 1 was used because the toxicity of ingested
CrVI has been extensively studied and the database is robust,
including many reproductive/developmental studies that have
been conducted in multiple species (e.g., mice, rats, monkeys,
rabbits). Importantly, the mouse endpoint used in this study for
derivation of the RfD (diffuse hyperplasia in the duodenum in NTP,
2008) is more sensitive than the reproductive/developmental ef-
fects that occur at higher doses and was the most sensitive
endpoint identiﬁed in USEPA (2010).
Accordingly, the RfD is calculated as follows:Cr/kg tissue)
95% LCLc
(added mg Cr/kg tissue)
Number of
animalsd (n)
Diffuse hyperplasiad
(# animals)
e 50 0
6.6 50 16
29.8 50 35
33.3 50 31
50.5 50 42
Fig. 4. Diffuse hyperplasia incidence versus duodenum tissue concentration.
Table 6
BMD modeling results for diffuse hyperplasia in the duodenum of B6C3F1 mice.
BMD modela Duodenum tissue concentration
dose metricb
AIC value Goodness-of-ﬁt
P value
Scaled residual
near BMD dose
BMD10 (added mg
Cr/kg tissue)
BMDL10 (added mg
Cr/kg tissue)
Log-logistic Mean added mg Cr/kg tissue 239.644 0.4658 0 1.83 1.41
Dichotomous-hill Mean added mg Cr/kg tissue 239.644 0.4658 0 1.83 1.37
Average: 1.83 1.39
Log-logistic 95% LCL added mg Cr/kg tissue 240.839 0.4379 0 1.74 1.21
Dichotomous-hill 95% LCL added mg Cr/kg tissue 240.839 0.4379 0 1.74 1.30
Average: 1.74 1.26
a USEPA BMDS version 2.5.
b From Table 5.
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3.3. Weight-of-evidence for the most scientiﬁcally-supported
carcinogenic MOA
3.3.1. Data relevant to the proposed cytotoxicity-induced
regenerative hyperplasia MOA
Over the past few years, many new studies have been conducted
to investigate and improve the scientiﬁc understanding of the MOAfor CrVI-induced carcinogenicity due to oral exposure. Some of
these studies have already assimilated and evaluated relevant study
data for MOA analyses under regulatory agency guidance (e.g.,
Thompson et al., 2011b, 2013a), while the results of other studies
have yet to be included in a formal MOA analysis (e.g., Thompson
et al., 2015a, 2015b, 2015c). Applying relevant guidance (e.g.,
USEPA, 2005) in a recent MOA analysis, Thompson et al. (2013a)
present evidence in support of a non-mutagenic, cytotoxic MOA
for CrVI carcinogenicity with the following key events:
 Absorption of CrVI from the intestinal lumen.
Fig. 5. Mouse duodenum tissue concentration versus daily dose.
Table 7
Duodenum best-ﬁtting model tissue concentration prediction.
Hill model (non-constant variance) equation: Y [tissue conc. in mg Cr/kg at
dose] ¼ intercept þ v*dosen/(kn þ dosen)
Parameters Inputs
Oral dose (mg/kg-day) 0.31 (oral POD)
Intercept 0.018
v 62.397
n 1.406
k 4.638
Y [tissue conc. in mg Cr/kg at dose] 1.39 (BMDL10)
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 Compensatory crypt regenerative hyperplasia.
 Clonal expansion of spontaneous mutations within the crypt
stem cells due to chronic proliferation, resulting in late onset
tumorigenesis.
Although reduction of CrVI to CrIII occurs in the gastrointestinal
(GI) tract (stomach, intestinal lumen) and is recognized as a
detoxiﬁcation process (e.g., De Flora et al., 1997), it is generally
acknowledged that reduction of CrVI in the GI tract prior to ab-
sorption and cellular absorption by target tissues are competing
rates (e.g., Proctor et al., 2012; Kirman et al., 2013). Consequently,
while these competing processes have recently been studied to
better understand them for purposes of PBPK modeling (Proctor
et al., 2012; Kirman et al., 2013), the occurrence of CrVI absorp-
tion from the intestinal lumen is not a topic of signiﬁcant scientiﬁc
debate. Accordingly, since absorption of CrVI from the intestinal
lumen is known to occur and is the ﬁrst event assumed (inherently
or explicitly stated) in both the proposed non-mutagenic and
mutagenic MOAs for CrVI-induced carcinogenesis (Thompson et al.,
2013a; McCarroll et al., 2010), scientiﬁc evidence demonstrating
this key event in the carcinogenicity study need not be presented
here (e.g., see Appendix J of NTP, 2008 and Table 8 of Kirman et al.,
2012).3.3.1.1. Villous cytotoxicity. In regard to the duodenum as the tissue
where most tumorigenesis occurred, NTP (2008) indicated that theincidences of diffuse epithelial hyperplasia were signiﬁcantly
increased in the duodenum of all exposed groups of male and fe-
male mice (see Tables 13, C4, and D4 of NTP, 2008). By contrast, the
incidence of diffuse epithelial hyperplasia in the jejunum was
signiﬁcantly increased only in the highest female mouse exposure
group (516 mg sodium dichromate dehydrate (SDD)/L). The
duodenal villi of exposed mice were described as short, broad,
blunt, and lined by densely packed, tall columnar epithelial cells
compared to those of the controls (see Plates 19 to 22 of NTP, 2008).
Frequently, the epithelial cells and cell nuclei were piled up in
multiple layers along the long axis of the villi and intestinal crypts
were elongated and generally appeared to contain increased
numbers of epithelial cells with increased numbers of mitotic ﬁg-
ures. Study authors concluded these lesions to be consistent with
regenerative hyperplasia secondary to previous epithelial cell
injury (NTP, 2008). That is, the study authors themselves cite these
villous effects as part of the evidence of cytotoxicity-induced
regenerative hyperplasia having occurred in the mouse tissues
where tumorigenesis occurred.
In regard to early suggestive evidence of cytotoxicity, cyto-
plasmic vacuolization occurred in the mouse duodenal villi at 170
and 60 mg SDD/L on days 8 and 91, respectively (see Table 4 of
Thompson et al., 2013a). Villous atrophy and crypt hyperplasia, on
the other hand, both occurred in the duodenum at 520 and
170 mg SDD/L on days 8 and 91, respectively. Generally, these
effects did not occur in the jejunum on day 8 and occurred to a
lesser extent on day 91 (e.g., lower incidences of crypt hyperplasia
in the jejunum at these doses compared to the duodenum). Both
crypt area and the number of enterocytes per crypt in the duo-
denum were signiﬁcantly increased at 170 mg SDD/L on day 91,
but crypt hyperplasia was unable to compensate for the apparent
villous damage (e.g., atrophy, blunting, and cytoplasmic vacuoli-
zation at 170 mg SDD/L on day 91) and maintain normal, healthy
duodenal villi (see Fig. 4(A), (D), and (F) of Thompson et al., 2013a).
As opposed to villous toxicity, cytotoxicity to crypt cells was not
evident (e.g., decreases in crypt area and the number of enterocytes
per crypt, not increases, would be expected as a result of crypt
enterocyte cytotoxicity; lack of treatment-related effects on crypt
mitotic and apoptotic indices). Thus, data indicate that CrVI-
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marily in the duodenum (consistent with the incidence of mouse
tumors).
In regard to genotoxicity, karyorrhectic nuclei (KN) and micro-
nuclei (MN) were assessed in both the crypt and duodenal villi at
doses corresponding to water concentrations up to 520mg SDD/L for
up to 90 days. In vivo assays are useful for further investigation of
genotoxicity produced in in vitro systems, and themammalian in vivo
MN test is especially relevant for assessing genotoxicity because
although theymay vary among species, factors of in vivometabolism,
pharmacokinetics, andDNArepairprocesses areactiveandcontribute
to the responses (OECD, 2014). There were no treatment-related ef-
fects induodenal crypts. Bycontrast, induodenalvilli, KN(clusteredat
thevilli tips) andMNwere signiﬁcantly increased at170and520mg
SDD/Londay8 andat60and170mgSDD/Londay91, respectively
(see Tables 5 and 6 of Thompson et al., 2013a). These duodenal villi
effect level data for cytogenetic damage correspond to those dis-
cussed above for cytotoxicity and indicate that theMN present in villi
did not originate in the crypt. Data fromamore recent 7-dayexposure
study (including a positive control group) also showed no treatment-
related effects on MN (MN, KN, or g-H2AX immunostaining) in
duodenal crypts (Thompson et al., 2015c). Accordingly, available data
indicate that bothCrVI-induced cytotoxicityandgenotoxicity occur in
the duodenal villi, not the crypt. This is consistent with villous
toxicity-induced regenerative hyperplasia in the crypt, absent any
direct cytotoxicity or genotoxicity in the crypt itself.
Lastly, while there are data to suggest that absorbed CrVI may
have induced intestinal oxidative stress throughout the 2-year
mouse NTP (2008) study and contributed to cytotoxicity in the
intestinal villi, these data are not essential for the demonstration of
the proposed key events or for the limited purpose of this paper
and are therefore not considered further here (see Thompson et al.,
2013a).
3.3.1.2. Crypt hyperplasia. Cytotoxicity-induced regenerative pro-
liferation may be viewed as a necessary, but not always sufﬁcient,
event for tumor formation for chemicals with a non-genotoxic/
cytotoxic carcinogenic MOA (Butterworth et al., 1995). Accord-
ingly, the occurrence of hyperplasia in target tissues such as the
mouse duodenum is relevant as long-term oral exposure to CrVI
may facilitate tumorigenesis through the induction of prolonged
regenerative cellular proliferation, increasing replication errors
and causing the accumulation of spontaneous mutations within
stem cells that reside in the base of the crypts (O'Brien et al.,
2013). As mentioned in the previous section, crypt hyperplasia
occurred in the duodenum at 520 and 170 mg SDD/L on days 8
and 91, respectively. This is consistent with the number of enter-
ocytes per crypt being statistically signiﬁcantly increased and the
duodenal crypt area being increased z45% following 7-day
exposure to 520 mg SDD/L (Thompson et al., 2015c; O'Brien
et al., 2013), and the crypt area being similarly increased
following 7-day exposure to 170 mg SDD/L with both crypt area
and the number of enterocytes per crypt in the duodenum being
statistically signiﬁcantly increased at 170 mg SDD/L on day 91
(O'Brien et al., 2013; see Fig. 4(D) and (F) of Thompson et al.,
2013a). In the jejunum, crypt hyperplasia occurred at 170 mg
SDD/L on day 91 (see Table 4 of Thompson et al., 2013a). The
increased incidence of crypt hyperplasia in the duodenum at
170 mg SDD/L (90%) and 520 mg SDD/L (90%) on day 91 is
reasonably consistent with the increased incidence of diffuse hy-
perplasia (74e88%) at those water concentrations in the 2-year
NTP study (e.g., see Table D-4 of NTP, 2008). While Thompson
et al. (2013a) did not report an increased incidence of crypt hy-
perplasia in the duodenum at 60 mg SDD/L on day 91, there was a
statistically signiﬁcant increase in the number of enterocytes percrypt following 7-day exposure to 60 mg SDD/L as well as a
relatively comparable increase following 90-day exposure
(although it did not achieve statistical signiﬁcance), and crypt area
was also increased (z45%) at 60 mg SDD/L on day 91 (see Table 1
and Fig. 1(F) of Thompson et al., 2015c and Fig. 2(D) and (F) of
O'Brien et al., 2013). Moreover, the recent Cullen and Ward (2015)
study does report an increased incidence of crypt hyperplasia for
the CrVI research project study at 60 mg SDD/L on day 91 (30%) as
well as for the 2-year NTP study (40%) at the same water con-
centration where diffuse hyperplasia was reported by NTP (2008).
Increased crypt hyperplasia and diffuse hyperplasia in the duo-
denum at 60 mg SDD/L and in the jejunum at 170 mg SDD/L
appear consistent with the water concentrations associated with
tumorigenesis (e.g., see Table D2 of NTP, 2008).
As a marker for crypt cell proliferation, the increases in Ki67
expression at 60 mg SDD/L on day 8 and at 170 mg SDD/L on days
8 and 91 add to the already overwhelming weight-of-evidence that
CrVI induces crypt hyperplasia at tumorigenic doses (see Fig. 4(H)
of Thompson et al., 2013a). Lastly, while it may be hypothesized
that CrVI-induced hyperplasia occurs subsequent to a mutation
(e.g., McCarroll et al., 2010), not only is there a demonstrated lack of
genotoxicity (e.g., increased MN, Kras mutation frequency, g-H2AX
immunostaining) in the crypts of exposed mice, but the strong
doseeresponse for diffuse hyperplasia without a commensurate
doseeresponse for focal hyperplasia is inconsistent with this hy-
pothesis (e.g., see Table D4 of NTP, 2008). By contrast, the available
data are consistent with regenerative proliferation secondary to
cytotoxicity, which was also the conclusion of the NTP (2008) study
authors. Additional discussion of data and information relevant to
this key event in the proposed MOA (e.g., increasedMyc expression
and signaling, duodenal crypt mitotic index (MI) and apoptotic
index (AI)) may be found in Thompson et al. (2013a) and related
papers (e.g., Kopec et al., 2012a, 2012b).
3.3.1.3. Mutagenesis in crypt cells. The detection of gene mutations
in target tissues (that initiate the carcinogenic process) following
in vivo chemical exposure through an environmentally-relevant
route is the strongest evidence for a mutagenic MOA. O'Brien
et al. (2013) measured Kras codon 12 GAT mutation frequency in
the duodenal epithelium of mice exposed to 0.3e520 mg SDD/L
drinking water for 90 days to assess the potential for CrVI-induced
mutation in the small intestine. Kras was selected because:
 It is often mutated early in human intestinal tumors;
 Codon 12 GGT to GAT mutation is commonly reported in human
duodenal tumors and accounts for approximately 12.6% of colon
tumors;
 It has been shown to contribute to small intestine tumorigenesis
in mice; and
 Results from several studies suggest Kras codon 12 GAT muta-
tion frequency to be a functional reporter of tumor initiation
and/or progression that is ampliﬁed during carcinogenesis with
mutational loading, perhaps even when the mutational speci-
ﬁcity of the mutagen is other than the G to A mutation
(Thompson et al., 2013a).
If mutation preceded and induced crypt proliferation (e.g.,
McCarroll et al., 2010), then the increase in crypt cells could also
increase the likelihood of detecting Krasmutations. However, there
were no treatment-related effects on Kras codon 12 GAT mutation
frequency, even at carcinogenic CrVI doses that increased crypt
proliferationwith 7- or 90-day exposure (see Fig. 6(A) of Thompson
et al., 2013a). The absence of these effects does not support mu-
tation being the inducer of crypt proliferation or an early, initiating
key event in the carcinogenic MOA.
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precedes proliferation, then given crypt hyperplasia as early as day
8 and the high incidence by day 90, alterations in adenomatous
polyposis coli (Apc) might be occurring early on (inactivating mu-
tations in Apc results in uncontrolled cell proliferation and early
onset of mouse small/large intestine adenomas through constitu-
tive activation of Wnt/b-catenin signaling pathway). Kopec et al.
(2012a, 2012b) collected toxicogenomic data in mice and rats
exposed to CrVI up to 520 mg SDD/L for up to 90 days. However,
there was no indication of changes in Apc expression that might
result from genetic or epigenetic silencing of the Apc gene, no in-
crease in b-catenin (Ctnnb1) expression level or indication of
Ctnnb1 activation (by transcription factor analysis) that would be
expected by loss of Apc, nor was there functional enrichment of
Wnt/b-catenin signaling pathways. The absence of these changes in
the small intestine of CrVI-exposed mice suggests that crypt hy-
perplasia and tumorigenesis are not likely the result of early genetic
or epigenetic changes related to Apc.
Data from more recent studies also support that DNA damage is
not an early, initiating key event in CrVI-induced tumorigenesis
(Thompson et al., 2015a, 2015b, 2015c). For example, Thompson
et al. (2015a) used X-ray ﬂuorescence (spectro)microscopy (m-
XRF) to assess Cr content in the villi and crypt regions of the duo-
denum from mice exposed to CrVI in drinking water (520 mg SDD/
L) for 13 weeks. Additionally, g-H2AX immunostaining was used to
assess DNA damage. As observed previously, CrVI exposure induced
villous blunting and crypt hyperplasia in the duodenum. g-H2AX
immunostaining was elevated in villi, but not in the crypt
compartment, consistent with m-XRF maps revealing mean Cr
levels >30 times higher in duodenal villi than in crypts (mean Cr
levels in crypt regions were reported to be only slightly above
background). Despite the Cr and elevated g-H2AX immunoreac-
tivity in villi, no aberrant foci indicative of transformation were
evident (see Table S4 of Thompson et al., 2015a). These in vivo study
ﬁndings provide additional support for a non-mutagenic MOA
involving chronic wounding of intestinal villi and crypt cell hy-
perplasia as opposed to anMOA involving direct Cr-DNA interaction
in intestinal stem cells as an initiating key event for crypt prolif-
eration and tumorigenesis.
In a drinking water study to assess crypt health along the entire
length of the mouse duodenum, mice were exposed up to 520 mg
SDD/L drinking water for 7 days (Thompson et al., 2015c). Crypt
enterocytes in “Swiss roll” sections were scored as normal, mitotic,
apoptotic, karyorrhectic, or as having MN (an oral gavage of 50 mg/
kg cyclophosphamide served as a positive control for MN induc-
tion). Exposure to 180 and 520mg SDD/L signiﬁcantly increased the
number of crypt enterocytes, whereas MN and g-H2AX immuno-
staining were not increased in the crypts of dosed mice. Treatment
with the cyclophosphamide, on the other hand, was reported to
signiﬁcantly increase crypt MN and qualitatively increase g-H2AX
immunostaining. While synchrotron-based X-ray ﬂuorescence
(XRF) microscopy revealed strong Cr ﬂuorescence in duodenal villi,
negligible Cr ﬂuorescence was present in the crypt compartment.
The data from this in vivo study do not support that CrVI adversely
affects (i.e., damages DNA in) the crypt compartment where in-
testinal stem cells reside as an early, initiating key event for crypt
proliferation and tumorigenesis. Rather, as negative genotoxicity
data in target tissue, these data add to the weight-of-evidence that
the MOA for CrVI-induced tumorigenesis in the mouse small in-
testine involves compensatory crypt enterocyte hyperplasia
induced by chronic villous toxicity.
Additional data and relevant information (e.g., weight-of-
evidence support from genomic ﬁngerprinting for mutagenic
versus non-mutagenic carcinogens, lack of increased MN or g-
H2AX immunostaining in the crypt) may be found in Thompsonet al. (2013a) and related papers (e.g., Thompson et al., 2012b,
2015a, 2015c).
3.3.2. Data relevant to the proposed mutagenic MOA
McCarroll et al. (2010) conclude that the weight-of-evidence
supports the plausibility that orally administered CrVI may act via
a mutagenic MOA for carcinogenicity. However, as these study
authors did not have the beneﬁt of being able to review and weigh
the substantial data generated through the CrVI MOA research
project, this conclusionwas based primarily on studies designed for
hazard identiﬁcation as opposed to MOA analysis, and on data from
non-target tissues as well as in vitro systems. Regardless, McCarroll
et al. propose the following MOA key events:
 Interaction of absorbed CrVI with DNA
 Mutagenesis
 Cell proliferation
 Tumorigenesis
The ability of absorbed CrVI reduced intracellularly to interact
with macromolecules such as DNA is not a topic of signiﬁcant sci-
entiﬁc debate. However, the potential role of CrVI-induced muta-
genicity in the MOA for tumorigenesis/carcinogenesis in the small
intestine of mice orally exposed to CrVI is the subject of scientiﬁc
debate. Therefore, since the downstream events (i.e., cell prolifer-
ation, tumorigenesis) in the proposed mutagenic MOA depend
entirely upon the ability of CrVI to induce mutations that initiate
carcinogenesis in target tissues, evidence relevant to this topic is
discussed here.
3.3.2.1. CrVI-induced mutagenicity and genotoxicity
3.3.2.1.1. In vitro. CrVI compounds are positive in themajority of
in vitro mammalian cell line tests, with their genotoxicity being
related to solubility/bioavailability to the targets (ATSDR, 2012).
Furthermore, genetic toxicology data show that CrVI can act as an
in vitro mutagen, causing point mutations in Salmonella typhimu-
rium and Escherichia coli and a concentration-response in mutant
colonies at nonactivated concentrations down to noncytotoxic
levels in these bacteria (see Table 1 of McCarroll et al., 2010). Mu-
tation formation (i.e., increased reversions) in these bacteria is
mitigated by the addition of S9, consistent with the extracellular
reduction of CrVI to CrIII by constituents of the microsomal S9 mix
and ﬁndings that CrIII itself does not induce revertants (Thompson
et al., 2013a). McCarroll et al. also report CrVI to be mutagenic in
Saccharomyces cerevisae, mammalian cell lines (e.g., Chinese ham-
ster ovary (CHO)), and mouse lymphoma cells, and clastogenic in
cultured CHO cells, mouse mammary FM3A carcinoma cells, and
human lymphocytes. S9 activation is generally not required to
detect the mutagenic effects seen in the in vitro studies. Thus, at
least in vitro, data indicate that CrVI has the capacity to be a direct-
acting mutagen (McCarroll et al., 2010).
In regard to other genotoxicity demonstrated in vitro, CrVI has
been shown to cause DNA damage/repair in bacteria, DNA-protein
crosslinks, DNA strand breaks and adduct formation in mammalian
and/or human cells, sister chromatid exchange in CHO cells, and
unscheduled DNA synthesis in human lymphocytes and ﬁbroblasts,
with DNA adducts being the most abundant form of genetic lesions
in mammalian cells. Based on this information, McCarroll et al.
conclude that CrVI is generally positive in vitro for multiple geno-
toxic endpoints. However, interpreting the relevance of in vitro
results to the in vivo conditions of interest presents challenges and
appears particularly problematic for CrVI (e.g., non-target tissue
results versus actual target tissues, in vitro conditions versus in vivo
drinking water exposure ad libitum where extracellular reduction
of CrVI occurs and competes with absorption along the GI tract,
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reduction of CrVI can result in cytoplasmic trapping outside the
nucleus, roles of oxidative stress, oxidative DNA damage, and
epigenetic effects such as DNA hypermethylation in producing
genotoxicity in vitro as opposed to direct DNA reactivity). Conse-
quently, the examination of in vivo data and their relevance to the
exposure of interest is important.
3.3.2.1.2. In vivo. McCarroll et al. (2010) rely on two assays to
demonstrate that CrVI has the ability to inducemutations in vivo. In
the somatic cell mouse spot test, statistically signiﬁcant positive
results (i.e., increased number of coat spots due to loss of the
dominant allele for coat color pigmentation through mutation or
another genetic event) were obtained in female mice dosed by
intraperitoneal (i.p.) injection with 10 mg/kg-day potassium chro-
mate on gestational days 8e10, but not 20 mg/kg-day potassium
chromate (see Table 2 of Knudsen, 1980). In the transgenic Muta™
Mouse assay with the lacZ gene as the mutational target, 40 mg/kg
potassium chromate via i.p. injection increased mutational fre-
quency in the bone marrow and liver (Itoh and Shimada, 1998).
However, results from Knudsen (1980) are equivocal (i.e., effects at
10 but not 20 mg/kg-day), and regardless, McCarroll et al.
acknowledge that data generated via the i.p. exposure route are not
relevant to the oral route of exposure. This is especially true given
that bolus i.p. doses initially bypass the liver and also bypass CrVI
reduction in the GI tract as an important protective detoxiﬁcation
mechanism, especially at doses within the reductive capacity of the
GI tract (e.g., De Flora et al., 1997), and that the mouse tissues
shown to be mutagenically responsive in these studies (i.e., mela-
noblasts, bone marrow, liver) are not the ones shown to be
tumorigenically responsive following oral exposure in NTP (2008)
(e.g., the small intestine/duodenum). Thus, these studies only
appear to show that environmentally- and physiologically-
irrelevant exposure to CrVI is capable of inducing mutation in
genes that do not initiate tumorigenesis in tissues that are not
relevant to the target tissues of concern for potential carcinogen-
esis. For example, although mutation occurred in the skin and liver
of mice exposed to doses of 2.7e5.4 mg CrVI/kg and 14 mg CrVI/kg,
respectively, a range essentially covering most of the tumorigenic
doses in the NTP (2008) study (e.g., 1.4e8.7 mg CrVI/kg-day in fe-
male mice), CrVI did not induce tumors in these tissues (e.g., see
Table D1 of NTP, 2008). It stands to reason that if mutagenicity (or
other genotoxicity) occurs in tissues that do not subsequently
develop tumors (e.g., liver, skin), then that mutagenicity is not a key
event (or a predictor of a key event) that initiates tumorigenesis for
the chemical in question so does little to elucidate key events in
how the chemical initiates cancer in target tissues, much less being
indicative of a mutagenic MOA. This applies to the high NTP study
doses and even more so to environmentally-relevant doses, which
are orders of magnitude lower (e.g., the mouse dose at the lowest
water concentration used in NTP, 2008 is over 70,000 times higher
than the approximate human dose corresponding to the 35-city
geometric mean drinking water concentration reported in EWG,
2010), considering the lack of mutagenicity/genotoxicity in mouse
duodenal crypt target tissue (e.g., Thompson et al., 2013a, 2015c) at
doses corresponding to drinking water concentrations that induced
tumorigenesis in NTP (2008) but still orders of magnitude higher
than those applicable to humans.
McCarroll et al. also summarize other in vivo gentoxicity data
(see Table 2 of McCarroll et al., 2010). Although the weight-of-
evidence for mutagenic potential and its relevance to the MOA
cannot be determined simply by the number of positive versus
negative genotoxicity study results (i.e., there are many important
considerations), rat data are mostly positive and show chromo-
somal aberrations, DNA-protein crosslinks, and DNA single strand
breaks in bone marrow, liver, and liver and brain, respectively.These effects were generally observed following oral gavage
exposure durations that varied from a single dose up to daily doses
for a year, with the exception of the liver DNA-protein crosslinks
that were found after three weeks of exposure via drinking water
(Coogan et al., 1991). The mouse data reviewed are also mostly
positive and show DNA strand breaks, MN induction and chromo-
somal aberrations, and DNA fragmentation in leukocytes, bone
marrow, and liver and brain, respectively. DNA strand breaks,
fragmentation, and chromosomal aberrations were observed
following oral gavage of single doses. While MN were induced in
the bone marrow of MS/Ae and CD-1 mice by i.p. injection of
20e80 mg K2CrO4/kg, oral doses higher than the species-speciﬁc
LD50 values (i.e., doses as high as 160e320 mg K2CrO4/kg) did not
induce MN when given by oral gavage in the same study (Shindo
et al., 1989). In regard to environmentally-relevant exposure,
McCarroll et al. point out that the three 3-month mouse drinking
water studies cited (including NTP, 2007) were negative for MN in
bone marrow. Additionally, MN were not induced in the bone
marrow, peripheral blood, and/or livers of BDF1 mice and pregnant
Swiss mice (or their fetuses) exposed via drinking water up to
500mg CrVI/L (5000 times the federal MCL) for up to 210 days or by
intragastric administration of 17.7 mg CrVI/kg, whereas a single i.p.
injection of 17.7 mg CrVI/kg bypassing the environmentally- and
physiologically-relevant oral exposure route was capable of pro-
ducing positive results (De Flora et al., 2006).
As mentioned previously, McCarroll et al. acknowledge that data
generated via the i.p. exposure route are not relevant to the
assessment of oral exposure, although the study authors deem the
data to support that CrVI is positive for genotoxicity in vivo and
provide qualitative information for hazard identiﬁcation. However,
these i.p. data only support positive in vivo genotoxicity through an
exposure route that is environmentally- and physiologically-
irrelevant and contrived to bypass the liver and the CrVI reduc-
tion that occurs in the GI tract. In addition to environmentally-
irrelevant dosing, these data and the bolus oral dose data only
show genotoxicity in tissues that are not relevant to the target
tissues of concern for potential carcinogenesis (NTP, 2008). For
example, although DNA fragmentation occurred in the liver and
brain of mice exposed at doses (1.9, 19, and 95mg/kg presumably as
Na2Cr2O7 in Bagchi et al., 2002; which would correspond to 0.75,
7.5, and 38 mg CrVI/kg) apparently encompassing the range of
tumorigenic doses in the NTP (2008) study (1.4e8.7 mg CrVI/kg-
day in female mice), Bagchi et al. attribute this to oxidative dam-
age rather than direct DNA interaction, and moreover, CrVI did not
induce tumors in these tissues (see Table D1 of NTP, 2008). Simi-
larly, while chromosomal aberrations (i.e., primarily breaks, but
some rearrangements) occurred in bone marrow at a gavage dose
(20 mg CrO3/kg or 10.4 mg CrVI/kg in Sarkar et al., 1993) similar to
the tumorigenic dose for the highest female mouse exposure group
in the NTP study (8.7 mg CrVI/kg-day) and DNA strand breaks
occurred in the leukocytes of mice at a gavage dose range
(0.59e9.5 mg K2Cr2O7 or 0.21e3.4 mg CrVI/kg in Danadevi et al.,
2001) similar to that in the NTP study, the NTP study identiﬁed
the small intestine (the duodenum in particular) as the target tissue
for CrVI-induced tumorigenesis. Furthermore, DNA damage did not
occur in lymphocytes at much higher i.p. doses (3.3e27 mg CrVI/
kg) or higher oral doses (z6e9mg CrVI/kg-day) in rats exposed for
3e6 weeks via drinking water (Coogan et al., 1991), or in the leu-
kocytes of human volunteers ingesting 5 mg CrVI as a single bolus
or 4 mg CrVI/day via drinking water for 15 days (2 L/day of 2 mg
CrVI/L drinking water for 15 days; Kuykendall et al., 1996). Again, if
genotoxicity (or mutagenicity) occurs in tissues that do not sub-
sequently develop tumors (e.g., liver, brain), then it stands to reason
that the genotoxicity is not a key event (or a predictor of a key
event) that initiates tumorigenesis for the chemical in question so
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cancer in target tissues, much less being indicative of a mutagenic
MOA. This applies to the high NTP study doses, and even more so to
orders of magnitude lower environmentally doses, considering that
doses corresponding to drinking water concentrations that induced
tumorigenesis in NTP (2008) did not induce mutagenicity/geno-
toxicity in mouse duodenal crypt target tissue (e.g., Thompson
et al., 2013a, 2015c).
3.3.3. Carcinogenic MOA guidance and weight-of-evidence
assessment
3.3.3.1. MOA guidance considerations. In doseeresponse assess-
ment, the approach for extrapolation below the observed data (i.e.,
threshold versus non-threshold) is based on the understanding of
the chemical's MOA at each tumor site (USEPA, 2005). There is no
default carcinogenic MOA, even for chemicals demonstrating
mutagenic activity when data on other possible carcinogenic MOAs
are lacking (USEPA, 2007). Furthermore, simply demonstrating
plausibility or even a positive weight-of-evidence for mutagenic
activity/potential is insufﬁcient to conclude that the MOA is in fact
mutagenic (TCEQ, 2012). Such a low scientiﬁc standard of proof for
demonstration of a mutagenic MOA is contrary to USEPA guidance
(USEPA, 2007) that states [emphasis added]:
The determination that a chemical carcinogen is capable of pro-
ducing mutation is not sufﬁcient to conclude that it causes speciﬁc
tumors by a mutagenic MOA or thatmutation is the only key event in
the pathway to tumor induction. For a chemical to act by amutagenic
MOA, either the chemical or its direct metabolite is the agent inducing
the mutations that initiate cancer.
This sets a reasonably scientiﬁcally-rigorous standard for
demonstration of a mutagenic MOA. Most speciﬁcally, to demon-
strate a mutagenic MOA for a speciﬁc tumor the weight-of-
evidence of scientiﬁc information must sufﬁciently support that
“either the chemical or its direct metabolite is the agent inducing
THE mutations that initiate cancer [emphasis added]” at the tumor
site. At the most basic level, this requires:
(1) Linking the chemical or a metabolite to mutations; and
(2) Linking those mutations induced by the chemical to the
initiation of cancer in target tissues (TCEQ, 2012).3.3.3.2. Weight-of-evidence assessment
3.3.3.2.1. Mutagenic MOA. For the present assessment of the
weight-of-evidence for the most scientiﬁcally-supported MOA, it is
noted that:
 McCarroll et al. (2010) acknowledge that data best suited to
support many aspects of the MOA framework were not available
at that time;
 Since that time, the CrVI MOA research project has generated a
great deal of data relevant to this very issue;
 The demonstration of mutagenicity/genotoxicity in non-target
tissues, especially through environmentally- and
physiologically-irrelevant exposure routes (i.p.), is not tanta-
mount to demonstrating CrVI-induced mutagenicity in target
cells as the key initiating event for carcinogenesis in the target
tissues of animals exposed through drinking water in vivo; and
 Such a demonstration is particularly irrelevant to the possible
MOA and potential for tumorigenesis in target tissues at
environmentally-relevant drinking water doses (e.g., mean of
0.001 mg/L based on 18,085 samples (see Table S5 of Thompson
et al., 2015a)  2 L/day 1/70 kg ¼ 2.9E-05 mg CrVI/kg-day)
that are orders of magnitude lower than even experimentaldrinking water doses not associated with target tissue geno-
toxicity (e.g., O'Brien et al., 2013; Thompson et al., 2015a, 2015c).
In regard to (1) above, the demonstration of CrVI-induced mu-
tations (or even genotoxicity), some high dose mouse oral gavage
and i.p. studies have produced genotoxicity in non-target tissues
(see Table 2 of McCarroll et al., 2010). However, CrVI-induced mu-
tations have only been demonstrated through an environmentally-
and physiologically-irrelevant exposure route (i.p.) and only in non-
target tissues (Knudsen, 1980; Itoh and Shimada, 1998). By contrast
and more importantly, entirely relevant drinking water studies
have not found CrVI-induced mutagenicity (or genotoxicity) in the
target tissue duodenal crypts (e.g., O'Brien et al., 2013; Thompson
et al., 2015a, 2015c). This is not particularly surprising given that
the conditions under which some chemicals may be shown to cause
genotoxicity (e.g., carcinogenic study- or environmentally-
irrelevant high doses or exposure routes, non-target cells or tis-
sues, in vitro) may not necessarily be predictive of mutagenic effects
in the carcinogenic study laboratory animal target tissues or the
target tissues of humans exposed to environmentally-relevant
doses (TCEQ, 2012). Thus, the relevance of the positive results,
obtained in non-target tissues under unrealistic conditions
contrived to produce positive results (e.g., environmentally- and
physiologically-irrelevant i.p. exposure), to the MOA in target tis-
sues under realistic exposure conditions (i.e., environmental
exposure through drinking water) is questionable at best. Based on
currently available evidence, sound scientiﬁc judgment dictates
that the negative mutagenicity/genotoxicity results obtained in
target tissues under conditions that are actually relevant to the
MOA operating in the NTP (2008) mouse study (i.e., at oral doses
relevant to the study and through the relevant exposure route)
should weigh more heavily in the weight-of-evidence for the most
scientiﬁcally well-supported MOA. For example, the following
mutagenicity/genotoxicity ﬁndings weigh heavily against data
previously construed to support that CrVI is inducing tumorigen-
esis in the mouse small intestine through mutagenicity as the
initiating, key event:
 The absence of increases in Kras mutation frequency effects;
 The absence of effects on Apc expression; and
 The absence of cytogenetic damage (e.g., elevated g-H2AX
immunoreactivity, MN) in the duodenal crypts of mice exposed
in vivo to tumorigenic doses (e.g., Thompson et al., 2015a,
2015c).
Rather, these data provide support to a non-mutagenic MOA
weight-of-evidence and are consistent with the absence of early
tumors and metastases in the 2-year NTP (2008) study, as well as
the absence of neoplastic lesions in the 90-day drinking water
studies (NTP, 2007; Thompson et al., 2011a, 2012a).
In regard to (2) above, linking CrVI-induced mutations (or even
genotoxicity) to the initiation of cancer in relevant target tissues
(e.g., mouse duodenum), there is scientiﬁc evidence to the contrary
(i.e., CrVI did not induce genotoxicity much less mutagenicity in
duodenal crypt target tissue). As alluded to above, relevant drinking
water studies designed to address this very question did not ﬁnd
mutagenicity (or genotoxicity) in the target tissue duodenal crypts
(e.g., O'Brien et al., 2013; Thompson et al., 2015a, 2015c). Addi-
tionally, although mutagenicity and genotoxicity have been
induced in some tissues under contrived conditions (e.g., liver, skin,
brain), CrVI did not induce tumors in those tissues in the carcino-
genicity study (NTP, 2008), which is also antithetical to the
demonstration of such a link. So the tissues where CrVI has been
shown to induce mutagenicity or genotoxicity in some studies did
not develop tumors in the NTP study, and CrVI-induced
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(duodenal crypts) where tumors subsequently developed in NTP
(2008) in CrVI MOA studies designed speciﬁcally to address this
issue. These facts are directly contradictory to the assertion by
McCarroll et al. that DNA damage inmouse leukocytes and rat livers
(Danadevi et al., 2001; Coogan et al., 1991) show a causal rela-
tionship between DNA damage and tumor induction (in different
tissues no less) for the NTP (2008) study.
In summary, current evidence cannot be reasonably construed
to support a weight-of-evidence that CrVI induces mutations that
are THE initiating event in CrVI-induced carcinogenesis of the small
intestine, which is the reasonably scientiﬁcally-rigorous standard
for demonstration of a mutagenic MOA (USEPA, 2007; TCEQ, 2012).
Based on the current database, the lack of relevant data demon-
strating even a prima facie case for a link between mutations (or
even genotoxicity) induced by CrVI and the initiation of tumori-
genesis in the mouse small intestine (e.g., duodenum) renders
additional discussion of amutagenicMOA and the limitations of the
McCarroll et al. (2010) analysis unnecessary (e.g., the dos-
eeresponse for DNA strand breaks in mouse leukocytes is not
particularly relevant for showing doseeresponse and time
concordance between mutagenicity and tumorigenesis in the small
intestine, particularly given that at the time it was known that a 9-
month mouse dose of 4.7 mg CrVI/kg-day from drinking water (a
clearly tumorigenic dose in NTP, 2008) was reported not to cause
target tissue genotoxicity in De Flora et al., 2008). Interested
readers may refer to Thompson et al. (2013b) for a discussion of
their perspectives on the limitations of the McCarroll et al. (2010)
study, which complement the data-based scientiﬁc arguments
made herein. Based on the objective evaluation of currently avail-
able information, it is concluded that the hypothesis that mutation
is the initiating key event in CrVI-induced intestinal carcinogenesis
is inconsistent with the weight-of-evidence (e.g., MOA data
collected from target tissue following relevant exposure, late tumor
onset in the NTP study, etc.).
3.3.3.2.2. Non-mutagenic MOA. Studies recently conducted for
the CrVI MOA research project provide critical target tissue-speciﬁc
data and a basis for MOA analysis that is much more relevant and
scientiﬁcally robust than that available previously. This new MOA
information addresses the major data gaps cited by McCarroll et al.
(i.e., target tissue studies for temporal/doseeresponse concor-
dance, cell proliferation/hyperplasia studies, reductive capacity
studies). For example, McCarroll et al. (2010) indicate that in vivo
mutation and duodenal hyperplasia studies with adequate dose
selection, sampling and harvest times, and consideration of site
concordance and exposure conditions would help inform the
overall analysis, and such studies are now available (e.g., O'Brien
et al., 2013; Thompson et al., 2013a, 2015a, 2015c). These studies
show that to continue to rely on a hodgepodge of disjointed data,
much of limited relevance, to support theoretical plausibility as a
foundation for establishing a mutagenic MOA in the face of more
directly relevant and deterministic MOA study data (e.g., O'Brien
et al., 2013; Thompson et al., 2015a, 2015c) would be against the
scientiﬁc weight-of-evidence based on currently available infor-
mation. For example, while McCarroll et al. (2010) cite the lack of
target tissue studies as a database weakness, study authors still
conclude that evidence of in vitro and in vivo mutagenicity in the
absence of cytotoxicity rules out cytotoxicity as a likely MOA.
However, mutation was only induced by CrVI in vivo through an
environmentally- and physiologically-irrelevant exposure route
(i.p.) and only in non-target tissues (Knudsen, 1980; Itoh and
Shimada, 1998), and the study authors acknowledge that data
generated via the i.p. exposure route are not relevant to the
assessment of oral exposure. Additionally, evidence that a chemical
is capable of producing mutation or other DNA damage underin vitro conditions (e.g., even at sub-cytotoxic concentrations in
bacterial strains) represents only the lowest hierarchal evidence to
be considered along with all other relevant evidence (USEPA, 2007;
TCEQ, 2012). On the other hand, target tissue data are highest on
the scientiﬁc evidence hierarchy for evaluating the likely MOA
(especially when collected following relevant exposure), and con-
trary to ruling out cytotoxicity as a MOA, provide support that:
 Mutagenicity/genotoxicity is not induced by CrVI in the target
tissue (duodenal crypts) of mice exposed to tumorigenic oral
doses through the relevant exposure route (drinking water);
 Indeed, cytotoxicity (and resultant compensatory hyperplasia)
occurs in target tissue early during exposure to tumorigenic
doses through drinking water (i.e., hundreds of days before the
ﬁrst tumors); and
 The likely carcinogenic MOA is compensatory crypt enterocyte
hyperplasia induced by chronic villous toxicity.
Data supporting a carcinogenic MOA weight-of-evidence of
compensatory crypt enterocyte hyperplasia induced by chronic
villous toxicity are discussed in Section 3.3.1 and in greater detail in
Thompson et al. (2013a). That study also contains additional dis-
cussions (e.g., doseeresponse concordance, temporal association,
plausibility, human relevance) based on reasonable scientiﬁc in-
terpretations of the data, including a discussion of the toxicological
similarities between CrVI and captan. For example, captan also
causes duodenal tumors and hyperplasia in mice (but not rats) with
a long time to tumor (NCI,1977). Although USEPA had hypothesized
that captan has a mutagenic MOA and calculated an SFo (Q1*) based
on intestinal tumors in mice, following third-party review and
reevaluation of relevant (e.g., MOA) data, the USEPA Ofﬁce of
Pesticide Programs ultimately determined that captan acts through
a non-mutagenic threshold MOA that requires prolonged irritation
of the duodenal villi as the initial key event and is not likely to be a
human carcinogen at doses not causing cytotoxicity and regener-
ative cell hyperplasia (Gordon, 2007; USEPA, 2004). Such high
human doses were considered unlikely (as with CrVI), and based on
the MOA weight-of-evidence the genotoxicity of captan does not
contribute signiﬁcantly to human carcinogenic potential at
environmentally-relevant doses (Gordon, 2007). While the addi-
tional discussions in Thompson et al. (2013a) need not be repeated
here, new studies relevant to the weight-of-evidence have subse-
quently been published.
Brieﬂy, Thompson et al. (2015a) demonstrated that g-H2AX
immunostaining was elevated in duodenal villi but not in the crypt
compartment of mice exposed to 180 mg CrVI/L drinking water for
13 weeks, consistent with mean Cr levels z37 times higher in
duodenal villi than in crypts. Thompson et al. (2015c) showed that
exposure to 21 and 180 mg CrVI/L signiﬁcantly increased the
number of crypt enterocytes, whereas crypt MN and g-H2AX im-
munostaining were not increased (see Section 3.3.1.3). The data
from these in vivo studies do not support that CrVI damages DNA in
the crypt compartment where intestinal stem cells reside as an
early initiating key event for crypt proliferation and tumorigenesis.
To the contrary, these data add to the weight-of-evidence that
already supports a non-mutagenic MOA as opposed to an MOA
involving direct Cr-DNA interaction in intestinal stem cells as an
initiating key event for crypt proliferation and tumorigenesis.
Similarly, a recent study investigating the mutagenic potential of
CrVI in the oral mucosa of Big Blue® transgenic F344 rats found that
28-day exposure to 180 mg CrVI/L did not signiﬁcantly affect
mutant frequency (Thompson et al., 2015b), adding to the weight-
of-evidence that CrVI-induced carcinogenicity is unlikely to be due
to a mutagenic MOA, especially at environmentally-relevant doses.
Additionally, a recent report contains results of a pathology peer
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of histologically-prepared duodenal specimen slides from the NTP
and CrVI MOA research project studies wherein B6C3F1 mice and
F344/N rats were exposed to SDD via drinking water (Cullen and
Ward, 2015). The primary purpose of the pathology review was
to determine: (1) the degree to which histopathological duodenal
ﬁndings differed between these studies; (2) the degree to which
ﬁndings in mice and rats were qualitatively different or similar; and
(3) whether ﬁndings likely represent a single pathological process
or independent responses. Some of the signiﬁcant ﬁndings include:
 Histopathological ﬁndings in the mice and rats of the NTP
(2007) and CrVI MOA research project (SRI, 2011a, 2011b) 90-
day studies were qualitatively similar, although the degree to
which animals were affected varied between study, species, sex,
and exposure duration prior to sacriﬁce;
 Each of the ﬁve major ﬁndings (i.e., atrophy/blunting of villi,
enterocyte vacuolization, single cell necrosis, histiocytic cellular
inﬁltrates, crypt epithelial hyperplasia) was identiﬁed to some
degree in both mice and rats;
 Generally, the prevalence and severity of ﬁndings tended to be
greater in mice, males, and the CrVI MOA research project ani-
mals, and with increased dose;
 Themajor reasons for the differences in results between the NTP
and CrVIMOA research project 90-daymouse and rat studies are
greater prevalence and severity of effects in the CrVI research
project animals (e.g., perhaps due to different sources for
strains) and differences in diagnostic interpretation (e.g.,
perhaps due to speciﬁc focus on, and scrutiny of, non-neoplastic
morphological changes in Cullen and Ward, 2015); and
 Several of the ﬁndings (i.e., atrophy/blunting of villi, enterocyte
vacuolization, single cell necrosis, crypt epithelial hyperplasia),
however, were qualitatively similar in mice and rats of the
different studies and appeared pathologically inter-related,
portraying a process in which regenerative crypt epithelial hy-
perplasia occurred as a sequela to CrVI-induced villous epithe-
lial cell damage.
Table 8 contains mouse histopathological prevalence data of
particular interest for the current paper (from Tables 2 and 10 of
Cullen and Ward, 2015 and Table 2 of Thompson et al., 2011a). The
prevalences of histopathological ﬁndings due to 7- and 90-day
mouse exposures in the CrVI MOA research project (SRI, 2011a)
are presented along with those from the 2-year NTP (2008) study.
Generally, across dose groups the prevalences of the various his-
topathological ﬁndings for the villi and crypts in the CrVI research
project 90-day study were within 30% of those for the 2-year NTP
(2008) study. Overall agreement between 90-day and 2-year re-
sults appears particularly good for the high water concentration
exposure group (520 mg SDD/L). For the lower water concentrationTable 8
Prevalence of non-neoplastic ﬁndings in the duodenum of female mice exposed to CrVI
Diagnosis 0 mg SDD/L 60 mg SDD/L
90 Daysa 2 Yearsb 90 Daysa 2 Yearsb
Villus:
Histiocytic cellular inﬁltrates 0/10 0/9 1/10 0/10
Atrophy/blunting 0/10 0/9 4/10 1/10
Enterocyte vacuolization 0/10 0/9 3/10 1/10
Single cell necrosis 0/10 0/9 0/10 2/10
Crypt:
Epithelial hyperplasia 0/10 0/9 3/10 4/10
a CrVI research project (e.g., SRI, 2011a) study slide review results from Table 2 of Tho
b NTP (2008) study slide review results from Table 10 of Cullen and Ward (2015).exposure groups (60 and 170 mg SDD/L), the prevalences of his-
tiocytic cellular inﬁltrates, atrophy/blunting, and enterocyte
vacuolization were higher in the 90-day study compared to the 2-
year NTP study, which had a higher prevalence of villous single
cell necrosis. On the other hand, epithelial hyperplasia of the
duodenal crypt was higher in the 2-year study across all water
concentration exposure groups. These data show duodenal villous
toxicity and hyperplasia at60 mg SDD/L for 90 days. Furthermore,
for both the 90-day and 2-year exposure durations, these effects
generally become progressively much more prevalent at higher
water concentrations (170 and 520 mg SDD/L), where duodenal
tumors were also much more prevalent. See Cullen and Ward
(2015) for all available data as well as a more full discussion of
study ﬁndings. Lastly, Bourdon-Lacombe et al. (2015) conclude that
gene expression proﬁling (i.e., Thompson et al., 2012b) successfully
supports a non-genotoxic MOA for CrVI-induced small intestine
tumorigenesis, stating, “heat maps using genes related to various
MOAs associated with carcinogenicity (e.g., cell cycle progression,
proliferation, oxidative stress and regeneration) clearly show that
chromium clusters with other non-genotoxic carcinogens and not
with chemicals that are genotoxic.”
Key considerations in the weight-of-evidence for the carcino-
genic MOA (e.g., dose-response and temporal concordance) are
given in Table 9. Based upon review of the current database,
including newly published studies, the current paper concurs with
Thompson et al. (2013a) and Health Canada (2015) that the weight-
of-evidence supports cytotoxicity-induced regenerative hyperpla-
sia (i.e., a threshold MOA) as the most scientiﬁcally well-supported
MOA. A summary of doseeresponse information relevant to the
MOA is provided in Table 10 (similar to Table 1 in Thompson et al.,
2013b). Based on available MOA analyses and data, compensatory
crypt enterocyte hyperplasia induced by chronic villous toxicity
should be considered as required but not always sufﬁcient to
induce the late onset intestinal tumorigenesis observed in NTP
(2008), and the non-linear threshold (i.e., RfD) approach should
be adopted for assessing the potential intestinal carcinogenicity of
oral exposure to CrVI.4. Discussion and conclusions
Conservative default procedures are intended to provide regu-
latory scientists with a health-protective approach in the absence
of sufﬁciently robust scientiﬁc data that justify an alternative, more
chemical-speciﬁc and toxicologically-predictive approach. While
this is an important function, these default procedures also allow
regulatory scientists to avoid decisive scientiﬁc judgments based on
the scientiﬁc weight-of-evidence and conducting doseeresponse
assessments accordingly (e.g., evenwith a robust scientiﬁc weight-
of-evidence for a non-mutagenic MOA, the lack of study data in a
given area can be deemed uncertainty and used almost indeﬁnitelyfor 7 days, 90 days, and 2 years.
170 mg SDD/L 520 mg SDD/L
7 Daysa 90 Daysa 2 Yearsb 7 Daysa 90 Daysa 2 Yearsb
e 10/10 9/10 e 10/10 10/11
0/5 10/10 3/10 3/5 10/10 10/11
3/5 8/10 5/10 5/5 7/10 7/11
e 0/10 3/10 e 6/10 7/11
0/5 6/10 8/10 3/5 7/10 10/11
mpson et al. (2011a) and Table 2 of Cullen and Ward (2015).
Table 9
Key considerations in the carcinogenic MOA weight-of-evidence.
Evidence for non-mutagenic MOA [based on target tissue
data following in vivo drinking water exposure]a
Scientiﬁc relevance and weightb Evidence for mutagenic MOA [based on
non-target tissue data following various
exposure scenarios/conditions]c
Mutagenic potential pertinent to NTP study tumors
(1) No increased Kras mutation frequency in target tissue
(i.e., duodenum) due to 90-day exposure to 0.3
e520 mg SDD/L drinking water;
(2) No DNA damage - negative results for MNd, KN, AI, MI,
and g-H2AX immunostaining in duodenal crypts due to
drinking water exposure for 7 and/or 90 days; and
(3) Additionally, no Apc involvement or increased Wnt/b-
catenin signaling due to 90-day drinking water
exposure.
>
þþ Target tissue 
þ In vivo þ/
þ Relevant Study Species for SI Tumors þ/
þ Relevant Exposure Route /þ
þ Relevant Dose(s) þ/
þþ Drinking Water Exposure /þ
⇦ High hierarchy of evidence data from target tissue.
⇦ Data collected following in vivo exposure of the most
relevant study species/strain via the most relevant
route, exposure scenario, and dosing regimen (e.g.,
drinking water ad libitum and NTP study drinking water
concentrations).
⇦ All target tissue data negative for mutagenicity and
genotoxicity.
(1) Positive mutagenicity results in vivo
in mouse skin, bone marrow, and
liver (transgenic Muta™ mouse) by
an environmentally- and
physiologically-irrelevant exposure
route (i.p.);
(2) Generally positive genotoxicity
results in vivo in non-target tissues
of rats andmice exposed via routes/
scenarios either entirely or largely
irrelevant to the NTP study (e.g., i.p.
and gavage as opposed to drinking
water exposure that produced
negative results in several 3-month
studies), except for one rat drinking
water study qualitatively positive
for DNA-protein crosslinks by elec-
trophoresis (negative by the well-
established alkaline elution
method) in the liver but negative in
lymphocytes (Coogan et al., 1991);
and
(3) In vitro, generally positive results
for mutagenicity/genotoxicity in
non-target tissue cells and bacteria.
CrVI-induced mutagenicity as the initiating event
(1) Same negative mutagenicity and genotoxicity evidence
in target tissue as above following 7- and/or 90-day
exposure; plus
(2) Signs of duodenal villous toxicity and initial signs of
hyperplasia (e.g., larger crypt area) begin as early as
day 8 at 170 mg SDD/L, the drinking water
concentration where signiﬁcant villous toxicity (e.g.,
100% prevalence of atrophy/blunting) and duodenal
crypt hyperplasia (i.e., prevalence, signiﬁcantly
increased enterocytes/crypt and crypt area) is also
found later at day 91;
(3) Only one tumor location in each species (portal of entry)
despite the presence of Cr in multiple tissues; and
(4) Tumors of the mouse small intestine did not occur in
the 90-day NTP study or early in the 2-year study
(451 days _, 625 days \) and were not associated
with lethality or metastases.
>
(same þ/ as above)
⇦ High hierarchy of evidence data from target tissue.
⇦ Data collected following in vivo exposure of the most
relevant study species/strain by themost relevant route,
exposure scenario, and dosing regimen (e.g., drinking
water ad libitum and NTP study drinking water
concentrations). ⇦ Data show target tissue (i.e.,
duodenal crypt) hyperplasia in the absence of
mutagenicity (and genotoxicity), but in the presence of
signiﬁcant villous toxicity (e.g., prevalent atrophy/
blunting), in addition to characteristics not indicative of
a mutagenic MOA.
(1) Same non-target tissue data as
above; plus
(2) DNA adducts on pSP189 plasmids
transfected into human ﬁbroblasts
immortalized with the SV virus and
then transfected into E. Coli MBL50,
which increased mutation
frequency; but
(3) Primarily, DNA strand breaks in the
leukocytes of mice exposed via oral
gavage (Danadevi et al., 2001), and
secondarily DNA-protein crosslinks
as evaluated qualitatively by elec-
trophoresis (but negative by the
well-established alkaline elution
method) in the liver (but not in the
lymphocytes) of rats exposed via
drinking water (Coogan et al.,
1991), neither of which are muta-
tions or in target tissue.
Doseeresponse concordance
(1) Increased duodenum tissue concentrations of Cr at
14 mg SDD/L for 90 days;
(2) Redox changes (GSH/GSSG) in the duodenum at
60 mg SDD/L for 7 days and 14 mg SDD/L for 90
days, with gene expression changes indicative of
oxidative stress at 60 mg SDD/L for 90 days;
(3) Signs of duodenal villous toxicity and initial signs of
hyperplasia (e.g., larger crypt area) beginning at
170 mg SDD/L for 7 days, and 60 mg SDD/L for 90 days
(e.g., 40% prevalence of villous atrophy/blunting, 30%
prevalence of crypt hyperplasia);
(4) Increased villous toxicity and signiﬁcant crypt
hyperplasia at 520 mg SDD/L for 7 days, with
increased villous toxicity (e.g., atrophy/blunting) and
duodenal crypt hyperplasia (i.e., prevalence,
signiﬁcantly increased enterocytes/crypt and crypt
area) beginning at 170 mg SDD/L for 90 days;
(5) Similar but increased villous toxicity and duodenal
crypt hyperplasia prevalence with further increased
enterocytes/crypt and crypt area at 520mg SDD/L for 90
days;
(6) Qualitatively similar results for villous toxicity and
crypt hyperplasia for the 2-year NTP study.
>
þþ Target tissue 
þ In vivo þ
þ Relevant Study Species for SI Tumors þ/
þ Relevant Exposure Route and Dose(s) þ
þþ Relevant Exposure Scenario /þ
⇦ High hierarchy of evidence data from target tissue.
⇦ Data collected following in vivo exposure of the most
relevant study species/strain by themost relevant route,
exposure scenario, and dosing regimen (e.g., drinking
water ad libitum and NTP study drinking water
concentrations).
⇦ Data are indicative of: (1) Increased tissue
concentrations of Cr and redox changes at lower
concentrations than those inducing villous toxicity and
crypt hyperplasia at the same time point; (2) Signiﬁcant
crypt hyperplasia (60% prevalence) at 520 mg SDD/L on
day 8 in the presence of signiﬁcant villous toxicity (e.g.,
60% prevalence of atrophy) and signs of villous toxicity
and initial signs of hyperplasia that began at the next
lowest dose of 170 mg SDD/L on day 8; (3) Signiﬁcant
crypt hyperplasia (30% prevalence) in the presence of
villous toxicity (e.g., 40% prevalence of atrophy/
To demonstrate doseeresponse
concordance between the key
mutational event initiating the
carcinogenic process in themouse small
intestine and subsequent events in the
hypothesized mutagenic MOA, the
McCarroll et al. (2010) analysis hinges
upon:
(1) Primarily, DNA strand breaks in
Swiss mouse leukocytes (a non-
mutation endpoint, not in a tissue
susceptible to CrVI-induced carci-
nogenesis) due to single oral gavage
at a cited dose of 0.6 mg/kge
(Danadevi et al., 2001); and
(2) Secondarily, DNA-protein cross-
links in the rat liver (another non-
mutation endpoint not in target
tissue) as assessed qualitatively by
electrophoresis (negative by the
well-established alkaline elution
method) at z6e9 mg CrVI/kg-day
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Table 9 (continued )
Evidence for non-mutagenic MOA [based on target tissue
data following in vivo drinking water exposure]a
Scientiﬁc relevance and weightb Evidence for mutagenic MOA [based on
non-target tissue data following various
exposure scenarios/conditions]c
(7) Mutagenicity/genotoxicity is not induced by these
drinking water concentrations - no evidence of
increased Kras mutations, crypt cytogenetic damage
(i.e., negative results for MNd, KN, AI, MI, and g-H2AX
immunostaining), Apc involvement or increasedWnt/b-
catenin signaling at tumorigenic doses via drinking
water for 7 and/or 90 days; and
(8) Late onset tumorigenesis is induced at the same
drinking water concentrations (60e520 mg SDD/L) as
these non-mutagenic events.
blunting) beginning at 60 mg SDD/L on day 91 that is
progressively more prevalent at 170 and 520 mg SDD/L
in the presence of increased and signiﬁcant villous
toxicity and in the absence of crypt mutagenicity/
genotoxicity; and (4) Qualitatively similar results for
villous toxicity and crypt hyperplasia in the 2-year
study.
⇦ Duodenal tumors occur at these same doses.
for 3 weeks via drinking water
(Coogan et al., 1991).f
Temporal concordance
Day 8
 Decreased GSH/GSSG ratio
 Nrf2 activation/oxidative stress
 Signiﬁcantly increased Cr content in duodenal villi
 Signs of duodenal villous toxicity (e.g., cytoplasmic
vacuolization, atrophy) and initial signs of hyperplasia
(e.g., larger crypt area) beginning at 170 mg SDD/L
 Absence of signiﬁcantly increased Cr content in duodenal
crypts
 Absence of aberrant nuclei (e.g., MNd, KN) or g-H2AX
immunostaining in duodenal crypts
 No Apc or Wnt/b-catenin changes
 Transcript changes consistent with non-mutagenic MOA
 Increased signs of villous toxicity and incidence of crypt
hyperplasia at 520 mg SDD/L
Day 91
 Decreased GSH/GSSG ratio
 Nrf2 activation
 Signiﬁcantly increased Cr content in duodenal villi
 Increased g-H2AX immunostaining in duodenal villi in
the absence of aberrant villous foci indicative of
transformation
 Diffuse hyperplasia at 62.5 mg SDD/L
 Signiﬁcant duodenal villous toxicity (e.g., atrophy/
blunting) and crypt hyperplasia beginning at 60 mg
SDD/L
 Absence of signiﬁcantly increased Cr content in duodenal
crypts
 Absence of aberrant nuclei or g-H2AX immunostaining in
duodenal crypts
 No change in Kras mutation
 No Apc or Wnt/b-catenin changes
 Increased and signiﬁcant villous toxicity and duodenal
crypt hyperplasia (i.e., prevalence, signiﬁcantly
increased enterocytes/crypt and crypt area) at 170 and
520 mg SDD/L
>
þþ Target tissue 
þ In vivo þ
þ Relevant Study Species for SI Tumors þ/
þ Relevant Exposure Route and Dose(s) þ
þþ Relevant Exposure Scenario /þ
⇦ High hierarchy of evidence data from target tissue.
⇦ Data collected following in vivo exposure by the most
relevant route, exposure scenario, and dosing regimen
(e.g., drinking water ad libitum and NTP study drinking
water concentrations).
⇦ Data are indicative of: (1) Signs of villous toxicity and
initial signs of crypt hyperplasia on day 8 at 170 mg
SDD/L, with increased villous toxicity and signiﬁcant
crypt hyperplasia on day 91 at the same dose; (2)
Signiﬁcant villous toxicity and crypt hyperplasia on day
8 at 520 mg SDD/L, with further increased villous
toxicity and signiﬁcant hyperplasia (e.g., prevalence,
crypt area) on day 91 at the same dose (in the absence of
cryptmutagenicity/genotoxicity); and (3) For the 2-year
study, qualitatively similar results for villous toxicity
and crypt hyperplasia.
⇦ Temporally, these effects occurring as early as day 8
signiﬁcantly precede the late onset duodenal tumors
(e.g., adenomas at 451 days).
To demonstrate temporal concordance
between key events in the
hypothesized mutagenic MOA for the
carcinogenic process in themouse small
intestine, the McCarroll et al. analysis
again hinges upon:
 Primarily, DNA strand breaks in Swiss
mouse leukocytes at day 1 due to
single oral gavage at a dose of 0.6 mg/
kge (Danadevi et al., 2001);
 Secondarily, after 3 week exposure to
z6e9 mg CrVI/kg-day via drinking
water (zday 21), DNA-protein
crosslinks in the rat liver (another
non-mutation endpoint not in a tis-
sue susceptible to CrVI-induced
carcinogenesis) evaluated qualita-
tively by electrophoresis (but nega-
tive by the well-established alkaline
elution method) (Coogan et al.,
1991)f; plus
 Cell proliferation (hyperplasia) at day
90.
2-Year (NTP Study)
 Qualitatively similar results for villous toxicity and crypt
hyperplasia
 Adenomas (451 days _, 693days \)
 Carcinomas (729 days _, 625 days\)
a Based on Tables 4, 7, 8, and 9 and Fig. 4 of Thompson et al. (2013b); Thompson et al. (2015a, 2015c), O'Brien et al. (2013), and Cullen and Ward (2015).
b While this column provides examples of important considerations for the weight-of-evidence, a simplistic consideration of these factors alone (e.g., the number of “þ” on
each side) would represent a signiﬁcant oversimpliﬁcation of the scientiﬁc judgment necessary for a weight-of-evidence determination as a more holistic consideration of the
data is necessary (e.g., cohesiveness of the data supporting a given MOA, interpretation of data obtained under different experimental conditions providing differing results
and its contextual meaning for the MOA and overall weight-of-evidence); “>” ¼ greater weight-of-evidence; “þ” ¼ attribute present; “” ¼ attribute absent; “þ/” or
“/þ” ¼ data having mixed attributes; “þþ” ¼ attribute considered of particular importance; SI ¼ small intestine; relevant ¼ same as the NTP (2008) mouse study that found
the tumors of the small intestine for which the underlying MOA is at issue.
c Based on Tables 1 and 2, Figs. 3 and 4, and text of McCarroll et al. (2010).
d Negative MN results from studies conducted by NTP (as cited in Table 2 of McCarroll et al., 2010) add to the weight-of-evidence.
e This dose cited by McCarroll et al. (2010) in units of mg Na2Cr2O7/kg should actually be in units of mg K2Cr2O7/kg (Danadevi et al., 2001); the corresponding Cr dose is
0.21 mg CrVI/kg.
f By contrast, although not noted by McCarroll et al. (2010) in the discussion of doseeresponse concordance, DNA damage (i.e., DNA-protein crosslinks) did not occur in
lymphocytes in Coogan et al. (1991) after 3 and 6 weeks of drinking water exposure toz6e9 mg CrVI/kg-day, doses that are considerably higher than the single oral gavage
doses in Dandevi et al. (0.21e3.4 mg CrVI/kg), and DNA damage did not occur in lymphocytes even at much higher i.p. doses (3.3e27 mg CrVI/kg in Coogan et al., 1991).
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ment and use of conservative defaults). Such undue reliance on
default procedures reduces scientiﬁc credibility, discourages
important new scientiﬁc research, and can reduce regulatory
chemical doseeresponse assessments to data collection andmodeling exercises that do not account for important chemical-
speciﬁc information or accurately reﬂect risk.
Regulatory doseeresponse assessment should be guided by
data-informed, chemical-speciﬁc approaches (e.g., low-dose
extrapolation, PBPK), in lieu of undue reliance on default
Table 10
Summary of doseeresponse data relevant to the MOA.
Responsea Drinking water concentration mg SDD/L
0.3 (0.1 mg CrVI/L) 4 (1.4 mg CrVI/L) 14 (5 mg CrVI/L) 60 (20 mg CrVI/L) 170 (60 mg CrVI/L) 520 (180 mg CrVI/L)
Cr in duodenum (villi) 7 7 ✓ ✓ ✓ ✓
Oxidative changes 7 7 ✓ ✓* ✓* ✓*
Gene expression changes 7 7 ✓* ✓* ✓* ✓*
Villus toxicity b 7 7 7 ✓ ✓* ✓*
Crypt hyperplasia b 7 7 7 ✓ ✓ ✓*
K-ras mutations 7 7 7 7 7 7
Crypt MN 7 7 7 7 7 7
Crypt DNA damage (g-H2AX) NA 7 NA 7 NA 7
a
✓ ¼ presence of response due to 90-day exposure, with “*” denoting that 7-day exposure also induced the effect; 7 ¼ absence of response; NA ¼ not assessed.
b From Table 8.
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defensible. Failure to do so may result in signiﬁcantly over-
estimating environmental risk and diverting governmental and
public attention away from more important public health issues
(e.g., obesity, cardiovascular disease, tobacco use), thereby leading
to misprioritization and misallocation of efforts and the limited
resources available. For example, the Coachella Valley Water Dis-
trict indicates that although no drinking water wells exceed the
federal MCL, treating water from the 30 wells that are above Cal-
ifornia's new CrVI standard of 10 ppb will increase water bills by
$30e50 per month just to comply with the standard, when their
customers' per capita income of approximately $22,000 per year is
already less than half the state average (CVWD, 2013, 2015a, 2015b;
CalDOF, 2015). In the present case, there are sufﬁciently robust
scientiﬁc data relevant to the carcinogenic MOA for CrVI to justify a
more data-informed, chemical-speciﬁc approach.
Accordingly, the current paper built upon the previous study
(Haney, 2015b) to develop both a non-linear, non-threshold
approach and a non-linear threshold approach for assessing the
oral carcinogenicity of CrVI. For the non-linear, non-threshold
approach, a doseeresponse function was developed (based on the
Weibull model) that adequately describes the non-linearity ex-
pected in human excess risk versus oral dose due to the sub-linear
relationship between oral dose and internal dose (added mg Cr/kg
target tissue) across the environmentally-relevant doses of regu-
latory interest (Figs. 1e3). For the non-linear threshold approach,
BMD modeling was used to derive an internal mouse POD (i.e.,
BMDL10 of 1.39 added mg Cr/kg duodenum tissue) for diffuse hy-
perplasia in the duodenum (Fig. 4 and Table 6). Modeling was then
used to convert this internal mouse dose to the corresponding
mouse oral POD of 0.31 mg/kg-day (Fig. 5 and Table 7). Using
applicable UFs (i.e., UFA of 10, UFH of 10, UFD of 1) resulted in an RfD
of 0.003mg/kg-day, which is considered protective of cytotoxicity-
induced regenerative hyperplasia as a key precursor event to
carcinogenesis in the mouse small intestine and happens to
correspond to the approximate human dose at the MCL (i.e., MCL
of 0.1 mg/L 2 L/day/70 kg ¼ 0.0029 mg/kg-day z 0.003 mg/kg-
day).
This RfD value (0.003 mg/kg-day) shows remarkable agreement
with that published previously (0.006 mg/kg-day) based on a more
scientiﬁcally-sophisticated approach that utilized extensive PBPK
modeling to address important factors such as human variation
(e.g., pH-dependent CrVI reduction across age groups, diurnal
variation in gastric lumen factors, sensitive subpopulations such as
PPI users) (Thompson et al., 2013b). Convergence of these two RfD
values derived using appreciably different methods increases
conﬁdence in candidate RfD values near or within this range
(0.003e0.006 mg/kg-day) that are based on more appropriate dose
metrics (i.e., dose metrics more closely related to the toxic effectsuch as internal dose to the critical target tissue as opposed to oral
dose). For example, Health Canada (2015) has just derived a toler-
able daily intake of 0.0044 mg/kg-day based on the weight-of-
evidence for a threshold MOA for CrVI-induced carcinogenesis via
oral exposure, which was used to calculate a proposed health-
based maximum acceptable concentration of 0.1 mg/L for CrVI in
drinking water. Comparison of the RfD values suggests that the RfD
derived in the current paper, which approximately corresponds to
human intake at the MCL, could be somewhat conservative. This is
consistent with negative results for villous toxicity, proliferation,
and the various other endpoints studied in the MOA research
project (e.g., Cr in duodenum, redox changes, gene changes, crypt
cytogenetic damage, Kras mutations, pre-neoplastic lesions) at the
MCL and the next higher water concentration, which was 14-fold
higher (see Table 1 of Thompson et al., 2013b).
The RfD approach is the most scientiﬁcally-defensible, non-
linear approach based on the weight-of-evidence of available MOA
information for the most scientiﬁcally-supported MOA. That is, as
the weight-of-evidence supports compensatory crypt enterocyte
hyperplasia induced by chronic villous toxicity as the carcinogenic
MOA for CrVI-induced carcinogenesis, an RfD should be developed
(USEPA, 2005). Health Canada (2015) concurs that the evidence for
a mutagenic MOA is weak, and conﬁdence in a cytotoxic MOA is
high. Despite the weight-of-evidence for a non-mutagenic MOA, if
the MOA were actually mutagenic, estimates of the potential risk
associated with an RfD of 0.003 mg/kg-day (excess risk of 1.8E-04
to 3E-04) would be near the upper end of the USEPA acceptable
excess risk range and lower than the risk associated with the
federal MCL for arsenic (excess risk of 5E-04 at 10 ppb based on the
USEPA IRIS drinking water unit risk of 5E-05 per ppb), which may
be deemed acceptable (Haney, 2015b). However, after due
consideration of the associated strengths, limitations, and other
factors in the context of public health protection, either the RfD
derived herein or an RfD based on a more scientiﬁcally-
sophisticated approach (e.g., Thompson et al., 2013b) may be
considered more appropriate.
5. Uncertainties
Extrapolation of experimental animal data to estimate potential
human cancer risk yields uncertainty. Although the risk estimates
contained in the non-linear, non-threshold section assume low-
dose linearity of target tissue dose (not oral dose) and risk (note
that a sub-linear doseeresponse results when risk is expressed as a
function of oral dose due to the non-linear relationship between
tissue dose and oral dose), based on the weight-of-evidence for a
cytotoxicity-induced regenerative proliferation (i.e., non-
mutagenic) MOA for carcinogenicity, actual risk for low oral doses
of CrVI (e.g.,0.006mg/kg-day) may be as low as zero. There is also
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the human doses and excess risk estimates in Table 1. That is, USEPA
BMD software may not contain all models that would ﬁt the data
and the doseeresponse function from another model might return
slightly different excess risk results at a given dose. However, the
model selected (Weibull model) provides good ﬁt to the full dataset
as well as data subsets (Table 3). Beyond this, the uncertainties
associated with the non-linear, non-threshold assessment are the
same as those associated with the toxicokinetic (i.e., dose-
dependent, dose fraction absorbed) analyses conducted in the
Haney (2015a, 2015b) peer-reviewed publications. Readers are
referred to those published, open access studies for additional
discussion of uncertainties.
Extrapolation of experimental animal data to humans also gives
rise to uncertainties for the non-linear threshold (i.e., RfD)
approach. In recognition of these uncertainties, UFs were applied to
the POD (i.e., BMDL10) in deriving the RfD. More speciﬁcally, stan-
dard UFs generally considered to account for the uncertainties
associated with a number of steps in extrapolating laboratory ani-
mal data to humans were used, including an UF for intrahuman
variability in susceptibility (i.e., a full UFH of 10 as well as a full UFA
of 10). Consistent with default procedures designed to be sufﬁ-
ciently conservative in recognition of the uncertainties associated
with deriving toxicity factors, it is important to note that PBPK
models are useful in accounting for interspecies and intraspecies
differences in pharmacokinetics, and the RfD value (0.006 mg/kg-
day) calculated by Thompson et al. (2013b) based on a more
scientiﬁcally-sophisticated assessment utilizing mouse and human
PBPK modeling that addresses key factors in human variation (e.g.,
pH-dependent CrVI reduction across age groups, diurnal variation
in gastric lumen factors, sensitive subpopulations such as PPI users)
suggests that the RfD derived herein (0.003 mg/kg-day) may
adequately account for such uncertainties.
The carcinogenic MOA weight-of-evidence also has associated
uncertainty. New scientiﬁc data continue to be generated and
published and it is possible that future studies appearing in the
scientiﬁc peer-reviewed literature with data relevant to the MOA
for CrVI-induced carcinogenesis due to oral exposure could affect
the scientiﬁc interpretation and/or weight of prior scientiﬁc data.
Additionally, while the CrVI MOA research project has been rather
extensive and was designed to ﬁll data gaps in the scientiﬁc un-
derstanding of the carcinogenic MOA, it can always be said that
residual scientiﬁc uncertainty remains. Readers are referred to the
individual MOA studies and analyses for discussions of the associ-
ated limitations by the respective study authors (e.g., Thompson
et al., 2011a, 2011b, 2012, 2013a; Kirman et al., 2012, 2013;
Proctor et al., 2012; Kopec et al., 2012a, 2012b; O'Brien et al.,
2013; Thompson et al., 2015a, 2015c; McCarroll et al., 2010).
However, the existence of some degree of uncertainty in a given
area does not change the weight-of-evidence for the most
scientiﬁcally-supported MOA based on the information currently
available, which supports the non-linear threshold (i.e., RfD)
approach as the most scientiﬁcally-defensible, non-linear
approach. Nevertheless, in regard to uncertainty surrounding the
carcinogenic MOA, Haney (2015b) evaluated what the potential
excess risk could be at various RfD values in the event that a
weight-of-evidence ﬁnding for a non-mutagenic MOA were incor-
rect, accounting for dose-dependent differences in absorption by
target tissues. Results indicated that despite the weight-of-
evidence for a non-mutagenic MOA, if the MOA was assumed to
bemutagenic, estimates of the potential risk associated with an RfD
of 0.003 mg/kg-day (excess risk of 1.8E-04 to 3E-04) would be near
the upper end of the USEPA acceptable excess risk range and lower
than the risk associated with the arsenic federal MCL (excess risk of
5E-04 at 10 ppb).Acknowledgments
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